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CHAPTER I 
 
BACKGROUND AND RESEARCH OBJECTIVES 
 
Introduction 
In theory, pathogen-specific T cell responses are capable of recognizing virtually 
every potential antigen (1); thus, appropriately tuned T cell responses can be an 
incredibly powerful component in the defense against infection. T cell responses 
are governed by myriad cellular signals which inform them to ‘go’ or ‘stop’ or 
‘speed up’ or ‘slow down.’ In chronic human immunodeficiency virus (HIV) 
infection, T cell responses are often unable to function normally upon stimulation. 
Understanding the cellular signaling networks that influence immune responses 
in chronic infections like HIV is crucial to our broader understanding how T cell 
immunity is initially generated and subsequently maintained over time. 
 
 
The context of HIV disease and research 
HIV remains a pressing public health concern in communities large and small. 
Advances in antiretroviral therapy (ART) (2-6), findings from vaccine trials (7, 8), 
detailed genetic studies (9), mathematical models of epidemiology (10, 11), as 
well as improvements in animal model systems (12, 13) have led us closer to an 
understanding of how HIV causes disease in humans. Ultimately, these 
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advances serve to highlight not only deficiencies in immune protection against 
HIV but also in our understanding of the processes which govern immunity. 
 
In the majority of natural HIV infections, the immune response is characterized by 
systemic immune activation and progressive immune dysfunction leading to the 
eventual collapse of the immune response and acquired immunodeficiency 
syndrome (AIDS) (14). There do exist a small number of infected individuals who 
suppress viral replication to very low levels for long periods of time in the 
absence of drug therapies (15-17), and so we presume that natural immune 
control of HIV replication is possible. Despite mammoth research efforts over 
nearly 30 years, concrete correlates of immune protection in HIV, such as 
minimum antibody titers or consistent T cell responses remain elusive. In HIV 
disease, the study of natural and effective immune responses and results from 
vaccine trials may be our best hope to establish useful correlates of protection. 
 
We can note that one recent human vaccine trial had high expectations for 
success and generated immune responses, but had no impact on infection rates 
(7) and another human trial with lower expectations for success actually 
conferred a modest degree of protection from HIV infection (8). The 
immunological and molecular details of these trials are being investigated 
intensely (18, 19). Even without achieving fully protective immunity, the data from 
these vaccine trials and others will provide useful insights into HIV 
immunopathogenesis.  
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Human HIV infection has likely been under greater scrutiny than any other 
disease system in history, and this intensive focus has advanced our 
understanding of immunology, virology, and host-pathogen interactions as well 
as diverse fields in the social, economic, and interventional sciences. The impact 
of this scrutiny on academic research is undeniable, far-reaching, and mostly 
comprised of independent searchers and researchers seeking to fit small pieces 
of knowledge into a rapidly advancing picture of human health and disease (20). 
My work is a piece of this puzzle directed toward understanding the molecular 
characteristics of the HIV-specific cytotoxic T lymphocyte (CTL) response in 
natural HIV infection as well as the molecular mechanisms that contribute to T 
cell dysfunction over time. These data also may provide useful insight into the 
immunopathogenesis of HIV infection.  
 
The host – pathogen interface 
The composition of immune systems in diverse mammals is stunningly similar 
(21), speaking to the long evolutionary history behind its current iteration in 
humans. The immune systems of mice are, in large part, representative of those 
found in primates, and immunity in non-human primates is an even better 
representative of human immunology. Thus, much of the foundational knowledge 
of immune function is derived from experiments conducted in small animal 
models which are more amenable to manipulation and experimentation than 
humans (22). The immune system, at its most basic level, is rooted in the idea 
that keeping self and non-self separate confers advantage to the host organism. 
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The segregation of self is of greatest import when considering the non-self actors 
represented by microbial pathogens seeking to infect (or invade) and parasitize a 
host.  
 
Compared to the human host, HIV has an incredibly short generational time and 
a capacity for very rapid evolution (23). The host immune response, on the other 
hand, has a great diversity of cells and corresponding functions to draw upon. An 
organism’s immune system is comprised of a variety of leukocytes (white blood 
cells) resident in tissues, circulating in the periphery, and stashed away in 
replenishing organs. The constant tension between microbes seeking to 
reproduce within a host and the host immune cells seeking to maintain the host’s 
integrity by denying pathogens a suitable environment for reproduction lends 
itself to military analogies. We often portray microbes as attackers and the 
immune system as the body’s defender. In anthropomorphized evolutionary 
terms, the pathogen and host are simply pawns as each organism attempts to 
maximize its reproductive potential which sometimes comes at the expense of 
the other (24). With HIV cast as the attacker in this case, and the human immune 
system acting as defender with many small but critical units, the stage is set to 
discuss this host-pathogen pair in more detail. 
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Innate and adaptive immune responses 
Innate immune responses are comprised of cells which have the capacity to 
recognize self from non-self at a relatively low level of resolution by identifying 
pathogens on the basis of common molecular characteristics. In a normal 
immune response, the sum of these initial immune responses either eliminates a 
pathogen and clears infection or slows its growth while also working to prime the 
development of an adaptive immune response. In this way, non-specific innate 
immune responses act as a bridge from initial pathogen recognition to the 
initiation of a pathogen-specific adaptive immune response.  
 
HIV has evolved several mechanisms to subvert innate responses, which 
indicates how important these initial steps are in the development of immune 
responses to the virus (25). Innate immune responses on their own are not likely 
to protect individuals from acquisition of HIV in many, if any, cases (26), and 
some features of the innate response may even contribute to increased viral 
replication (27, 28). Infection of host cells is but one of the tactics HIV employs 
(as do all viruses) to avoid recognition by parts of the innate immune response 
and impair subsequent host immune responses. 
 
In contrast to innate immune responses which are non-specific but recognize 
invading pathogens rapidly, adaptive T cell responses are somewhat slower in 
their initiation, but they identify pathogens at a much higher level of resolution. T 
cells (leukocytes expressing an immunoglobulin T cell receptor) are activated in 
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response to specific physical and chemical signals from innate cells which have 
come in contact with a pathogen. T cells recognize pathogen-derived peptide 
antigens (epitopes), mount a defense which is diverse in function, eradicate the 
pathogen, and eventually, and ideally, contract to form memory cells which can 
reactivate more rapidly and defend more vigorously upon secondary infection or 
re-exposure to the pathogen (29). The ideal process of antigen recognition, 
expansion, clearance, and contraction is marked by dysfunction on a number of 
levels in natural HIV infection (30-33), and some of the factors which contribute 
to impaired T cell immunity form the basis for this dissertation research.  
 
Antigen presentation and epitope variability 
A critical component of the adaptive immune response is successful antigen 
presentation on the surface of cells which have been exposed to or infected by a 
pathogen. Antigen presenting cells (APC) can be professional leukocytes 
dedicated to the task of scouring the body for antigens and activating 
lymphocytes (specialized leukocytes) with specific signals or they might be non-
leukocyte, pathogen-infected cells. Often, professional APCs comprise part of the 
innate immune response itself. In the case of viral infections like HIV, antigen 
presentation takes place on the surface of HIV-infected cells, which also often 
happen to be a specific sub-set of T cells. HIV-infected cells can harbor actively 
replicating virus, and if replication is allowed to proceed, infected cells can 
produce millions of infectious viral particles per day (23). Subsequent recognition 
of HIV-infected cells by HIV-specific T cells can lead to killing of the infected cell 
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before the viral life-cycle is complete and results in suppression of viral 
replication.  
 
As a part of cellular protein synthesis, especially synthesis of viral proteins in 
infected cells, small peptide fragments are produced and are presented on the 
cell’s surface in complex with surface molecules known as major 
histocompatibility complex (MHC) proteins. MHC-I molecules are immunoglobulin 
cell-surface proteins specifically recognized by T cells expressing the CD8 co-
receptor. A binding cleft in the membrane distal domain of the MHC-I protein can 
bind small peptide epitopes from protein synthesis. Each different MHC-I 
molecule is derived from a distinct MHC-I gene and is capable of binding a set of 
protein peptide epitopes. Figure 1-1 provides a schematic diagram of the MHC-I 
molecule.  
 
Epitopes bound in MHC-I molecules are usually between 8-14 amino acids in 
length and restricted in structure and sequence such that they can make stable 
molecular interactions with amino acids lining the MHC-I binding cleft. The 
complex comprised of a peptide epitope bound within the cleft of the MHC-I 
molecule is known as a peptide-MHC-I complex (pMHC).
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Figure 1-1 – Class I Major Histocompatibility Complex. 3 alpha-subunits are 
shown with the B-microglobulin protein.  At the membrane distal region the 
epitope binding cleft is formed by the alpha-1 and alpha-2 subunits. Graphic 
adapted from atropos235, Wikimedia commons. 
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Human populations retain an exceptional diversity of and in MHC genes, 
especially in the MHC-I family of genes which number in the thousands of alleles 
and likely represent a necessity for the population to preserve the capacity to 
present many different peptide antigens. Every individual expresses several 
different MHC-I genes, and it is this complement of surface proteins which allows 
for a distinct set of pathogen peptides to be displayed. Genetic studies indicate 
that the expression of MHC alleles and their role in moderating T cell responses 
are critically linked to disease outcome [9, 34] which serves to reinforce the 
importance of T cell responses in the defense against HIV infection.  
 
Suppression of viral replication by T cells represents a powerful selective force in 
the evolution of viral genetic sequences which can be observed in both the global 
HIV population as well as within intra-individual HIV populations. The HIV-
reverse transcriptase protein is responsible for copying HIV RNA into viral DNA, 
and it makes many errors as it transcribes the genetic information (34, 35). Many 
of these errors result in the production of viruses which cannot replicate, 
however, random errors sometimes result in mutations that improve viral fitness 
and provide advantage under selection pressure. Recent research indicates that 
up to two thirds of viral mutations may occur as a result of T cell selection 
pressure (36, 37). Considering the potential variability of T cell epitope 
sequences in HIV, T cells with a capacity to cross-react with multiple viral 
epitopes may be valuable as the immune response seeks to recognize and 
suppress viral variants. 
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Development of T cells 
T lymphocyte progenitors are found in the bone marrow and migrate to the 
thymus for maturation through a course of proliferation, differentiation, and 
positive and negative selection events. The T cell receptor (TCR) complex on the 
cell surface is the defining structure for T lymphocytes, and in ~95% of circulating 
T cells, it is comprised of a set of dimerized alpha (α) chain and beta (β) chain 
immunoglobulin superfamily proteins. TCR α and β chain genes are rearranged 
during the maturation process to produce variable and unique protein surface 
dimers capable of recognizing pathogen epitopes. 
 
The initial expression of a TCRβ chain and the successful pairing of that 
molecule with a TCRα chain forms a functional TCR that locks the T cell into 
expression of a single TCRαβ dimer. Future activation and clonal expansion of 
this T cell will result in a genetically and structurally identical population of sister 
T cells. T cells expressing unique, clonal TCR are selected in the thymus through 
a series of deterministic events which ensure that the TCR can recognize and be 
activated by non-self antigens presented in the context of an individual’s 
expressed MHC molecules, but that these cells are not overly reactive in 
response to self-antigens. This process is repeated millions of times and 
produces a diverse population of T cells with the ability to recognize many 
different pathogen epitopes. 
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Through selection and recombination from various germline sequences during T 
cell maturation, and with the addition of random nucleotides between the 
recombined and rearranged TCR gene segments, each chain of the αβTCR has 
a similar structural backbone but also encodes a unique sequence of amino 
acids in its three hypervariable, complementarity determining region (CDR) 
loops. The first and second CDR loops are responsible for most of the TCR's 
affinity for major histocompatibility complex (MHC) molecules while the third CDR 
loop (CDR3) is primarily responsible for discrimination of different peptides bound 
by the MHC. The unique amino acid sequences within the CDR3 can be used to 
determine T cell clonality. The research reported in this dissertation focuses on 
the properties of expansions of epitope-specific clonotypes identified in this 
manner.  
 
Appropriate recognition of the host’s MHC molecules is a critical component of 
the T cell selection process and is concurrent with selection for T cells that 
recognize pMHC-I in a relatively narrow range of affinities (29, 38). The TCR 
complex found on the surface of functional T cells is comprised of several 
invariant CD3 and co-receptor molecules, that aid in the physical connection 
between the TCR and pMHC (TCR:pMHC). These molecules also coordinate 
and carry signals from the exterior of the cell across the membrane and into the 
cell where the signals are distributed into a variety of signaling pathways with 
overlapping and unique functions. Figure 1-2 provides a schematic diagram of 
the TCR molecule. 
12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-2 – The TCR antigen receptor/CD3 signaling complex in proximity 
to pMHC. Schematic diagram of the TCR dimer (red box) with invariant CD3 
signaling complex (blue boxes). Figure adapted from Paul WE, Fundamental 
Immunology, 2008. 
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T cell antigen recognition and activation 
T cell activation is an extraordinarily complex series of physical connections 
between T cell and APC. Bi-directional signal transduction events originate at the 
cell surface and cascade through each cell with broad effect, eventually initiating 
distinct transcriptional programs leading to protein production and phenotypic 
changes. The CD8 co-receptor on T cells serves to enhance and stabilize the 
physical TCR:pMHC connection and likely also serves to recruit intracellular 
signaling molecules proximal to the TCR complex on the inner surface of the 
membrane (29). 
 
Initial T cell activation has been simplified into a 'two signal' hypothesis (39, 40) 
whereby an initial signal derived from the binding of a T cell’s antigen receptor to 
its cognate pMHC complex confers specificity to the ensuing response. A 
second, TCR independent, signal is transduced through one or more 
immunoregulatory receptor molecules which license T cell activation and 
enhance function, clonal expansion, and differentiation (41). Importantly and 
recently, investigators discovered that many T cells also express inhibitory 
immunoregulatory receptors which serve to attenuate or limit cellular activation 
(42-46). Figure 1-3 provides a schematic diagram of the two signal paradigm for 
T cell activation.
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CD80/CD86
CD28
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-3 – Productive activation of T cells requires an antigen 
independent co-stimulatory signal. Schematic diagram depicting TCR:pMHC 
contacts, signal 1 (red box), and the prototypical CD28/CD80(86) co-stimulatory 
signal 2 (blue box). Figure adapted from Paul WE, Fundamental Immunology, 
2008. 
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The TCR-CDR3 loops (especially that of the TCRβ chain) confer much of the 
specificity a particular TCR, and thus a particular T cell, has for its optimally 
preferred (cognate) peptide antigen – Signal 1 (38). In reality, a single TCR can 
recognize many peptide epitopes that are structurally similar but may differ in 
sequence known as the T cell’s capacity for cross-reactivity. The strength with 
which the TCR binds to pMHC influences T cell function and phenotype and, to a 
large degree, ability to suppress viral replication (47). 
 
A prototypical stimulatory second signal occurs between the CD28 receptor 
molecule expressed on activated T cells and CD80 (B7.1) and CD86 (B7.2) 
ligand molecules expressed on the APC surface (41, 48). Ligation of the CD28 
molecule triggers a signaling cascade that has far-reaching effects including 
intracellular calcium release. Calcium release enhances cell trafficking, 
proliferation, and differentiation programs, phosphorylation of intracellular 
signaling molecules which eventually initiate T cell specific gene production in 
support of continued function, and even cytoskeletal rearrangements which 
promote and enhance cell contact and formation of a long-lived immune 
synapse. Activation of T cells also often triggers the release of granules 
containing pre-loaded with cytokines and cytotoxic molecules necessary for 
effector function and for the killing of virally-infected cells (29). In fact, strong 
expression, production, and release of cytolytic granules has been linked to 
control of viral replication (49), and poor expression has been linked to T cell 
dysfunction in chronic HIV infection (33). 
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More recent advances in the understanding of immunoregulatory molecules and 
signaling networks downstream of the initial TCR signal suggest that the ‘two 
signal’ model is likely oversimplified, although it remains a useful point of 
reference (50). An early finding, which helped to launch the field of inhibitory 
receptor signaling, was that activated T cells also express the cytotoxic T 
lymphocyte antigen-4 (CTLA-4) surface receptor.  CTLA-4 is structurally related 
to CD28, expressed shortly after cellular activation, and like CD28, also binds 
CD80 and CD86 but transduces an inhibitory signal which reduces T cell 
activation and proliferation (44-46). The notion that second signals could inhibit 
antigen-specific T cell activity suggested a molecular mechanism which could 
mediate immune tolerance, autoimmunity, and immunopathology. Since the 
discovery of CTLA-4 as an inhibitory immunoregulatory receptor, several other 
molecules have been identified and characterized which have similar T cell 
regulatory properties, among them, Programmed Death-1 (PD-1) (51, 52). 
 
T cell responses in HIV infection 
HIV infection results in high viral loads and widespread immune activation, each 
of which likely contributes to a progressively dysfunctional immune response. 
Numerous studies in human and non-human primate models confirm that CD4+ 
T cells in the mucosa are almost completely depleted in early infection and are 
not repleted as fully as those in the periphery (53-55). The incurred loss of gut 
immunity allows for the translocation of microbes and microbial products such as 
lipo-polysaccharide (LPS) across the intestine which contributes to further 
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increases in immune activation.  Increased activation, in turn, exacerbates HIV 
infection as greater numbers of activated T cells serve as targets for viral 
infection and replication (56). Peak viremia of millions to tens of millions of copies 
of HIV RNA per mililitre of peripheral blood occurs within about 14 days of initial 
infection (57). Studies of the relatively benign natural infection of sooty mangabys 
with SIVsm indicate that the enhanced immune activation seen in humans may 
play an important role in the progressive acquisition of immunodeficiency not 
seen in natural hosts (58, 59). One of the few direct immune correlates of 
disease progression in humans is the positive association between the activation 
marker CD38 and viral load and its negative correlation with CD4 T cell counts 
(60, 61). 
 
T cell responses appear in vivo coincident with initial reductions in HIV viremia 
and several studies indicate that they contribute directly to suppression of viral 
replication (62-65). The extent of their contribution to initial control remains 
incompletely defined in large part due to the recent discovery that the CD4+ T 
cell compartment is decimated very early in infection and thus the cells HIV 
replicates within are gone (53-56, 66). Depletion of CD8+ T cells in SIV infection 
of macaques results in increasing viral loads, and decreases in viral loads are 
associated with the repletion of those cells (63, 64). Specific viral immune escape 
mutations are temporally associated with loss of control of viremia as the 
recognition of viral epitopes by TCR is abrogated (36, 62, 67).  
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Several additional lines of evidence suggest that epitope-specific T cell 
responses drive HIV genetic evolution to escape T cell recognition (68, 69) and 
that individuals expressing rare MHC alleles have delayed disease progression 
that is related to expression of specific MHC alleles (9, 70, 71). Much of this 
evidence supports the idea that epitope-specific CD8+ T cell responses are a 
major component to the initial control of HIV viremia in acute infection as well as 
the primary contributor to suppression of ongoing viral replication during chronic 
HIV infection. 
 
T cell dysfunction and impaired memory development in the setting of poor or 
incomplete CD4+ T cell help have been described for some time (72-74), 
although the exact mechanisms by which CD4+ T cells ‘help’ CTL are not 
precisely known (75). T cell dysfunction in the setting of chronic viral infection 
and ongoing antigen exposure and not always as a result of the loss or absence 
of CD4+ T cells has been noted in numerous infection systems including mouse 
LCMV (76-78), SIV infection in macaques (59), as well as in human HIV and 
HCV infections (33, 72, 79, 80) and represents a pressing issue in natural 
infection. 
 
Dysfunctional or exhausted T cells are partially or wholly impaired for cytokine 
production, granule release, proliferation, and survival (80-83). It remains unclear 
whether T cell dysfunction in HIV is directly attributable to the dramatic loss of 
CD4+ T cells and the help they provide or to the persistence of viral antigen 
19 
exposure, but both features of HIV immunopathogenesis likely play major roles. 
Progressive T cell dysfunction occurs over time in many chronic infections and 
results in a hierarchical and predictable loss of effector T cell functions (77) 
beginning with high level functions like proliferation and production of IL-2 and 
ending with full functional exhaustion and eventual deletion. The inhibitory 
receptor molecule PD-1 has recently been identified as playing a significant and 
partially reversible role in regulating T cell function in chronic infections like HIV 
(78, 84-86). 
 
Structure, function, and signaling in the PD-1 pathway  
A role for the 288-amino acid programmed death-1 (PD-1 also CD279) in 
regulating apoptosis was determined through a genetic screen of B cell 
hybridomas undergoing cell death (51). Subsequent investigations of genetically 
engineered mice without the gene encoding PD-1 (Pdcd1) (knockout mouse = 
Pdcd1-/- ) suffer from various T cell mediated autoimmune disorders and Pdcd1-/- 
on autoimmune-prone backgrounds have accelerated immunopathological 
phenotypes (87, 88). Continued study of these phenotypes revealed PD-1’s 
important role in mediating T cell function, especially in autoimmunity and T cell 
tolerance (89). Further characterization of polymorphisms in the human Pdcd1 
gene brought to light associations with rheumatoid arthritis and systemic lupus 
erythematosus (90, 91). The identification of the primary ligand molecules for PD-
1 (PD-L1 and PD-L2) and subsequent characterization of their tissue distribution 
throughout the periphery on cells within epithelial and endothelial tissues as well 
20 
as wide expression within the immune compartment suggests that the PD-1 
pathway is involved in both peripheral and central tolerance (92). 
 
The extracellular domain of PD-1 shares close structural similarity with other 
immunoregulatory CD28-superfamily members CD28, CTLA-4, and BTLA (B and 
T lymphocyte attenuator) and has no intrinsic enzymatic activity. Rather, it seems 
to serve as an adapter molecule receiving its extracellular signal in ligand binding 
and then functioning to recruit other signaling molecules to the intracellular side 
of the immune synapse (93). 
 
Natively monomeric, PD-1 is a 288 amino acid transmembrane immunoglobulin 
(Ig) surface protein. The extracellular, N-terminal Ig-variable-like domain binds 
with its two ligands, PD-L1 (B7H1) and PD-L2 (B7H2). PD-L1 is widely 
expressed and is thought to be the ligand most responsible for PD-1’s influence 
attenuating autoimmunity. PD-L1 knockout mice have a severe and early 
autoimmune phenotype. PD-L2 expression is limited to APC and activated 
lymphocytes and is responsible for attenuating active, antigen-specific immune 
responses (92). Interestingly, the crystal structure of PD-1 bound to PD-L1 has 
extremely high homology to the antigen binding domain of antibodies (94) 
perhaps suggesting that the receptor:ligand complex could have an independent 
affinity for a third molecule further complicating this signaling pathway. 
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PD-1 is thought to discharge its inhibitory role by recruiting phosphatase 
enzymes to the inner cell membrane during an active immune response. Putative 
phosphatases would subsequently interact with signaling proteins downstream of 
the activated TCR and dephosphorylate activated proteins, thereby dampening 
the early immune response (95). Recruitment activity has been localized to the 
~70 amino acid cytoplasmic tail, which contains two canonical signaling motifs, a 
membrane proximal immunoreceptor tyrosine-based inhibitory motif (ITIM) and 
membrane distal immunoreceptor tyrosine-based switch motif (ITSM) in an 
identical arrangement to the CD33-related sialic acid binding Ig-like lectin (Siglec) 
proteins. The inhibitory motifs may recruit protein tyrosine phosphatases Src 
homology region 2 domain-containing phosphatase-1 (SHP-1, PTPN6) and SHP-
2 (PTPN11) in addition to other unknown inhibitory factors (96). The SHP-1 and 
SHP-2 phosphatases, although likely active in PD-1 signal inhibition, have not 
been directly demonstrated in concert with PD-1 signaling, which suggests that 
PD-1 may recruit these as well as yet unidentified inhibitory molecules to the 
membrane (93). 
 
Upon the engagement of PD-1 with its ligands, various phosphatases are 
recruited to the cytoplasmic face of the membrane. While the specific 
phosphatase molecules remain unknown, inhibitory signaling pathways 
downstream of PD-1 ligation are better defined. PD-1 engagement blocks 
phosphoinositol-3-kinase, and through inhibition of PI3k, PD-1 decreases 
resistance to apoptosis and reduces the cell’s capacity to utilize glucose, two 
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global pathways which negatively influence T cell activation. PI3k induces 
expression of Bclxl, which itself is an inhibitor of apoptosis, and experimental 
evidence suggests that increased PD-1 expression is associated with increased 
cell death. Furthermore, PI3k also induces expression of Akt, which upregulates 
proteins necessary for glucose metabolism and provides experimental evidence 
linking expression of PD-1 to reduced proliferative capacity (95). Recent gene 
expression analysis in epitope-specific T cells also suggests that PD-1 ligation 
also serves to upregulate basic leucine transcription factor ATF-like (BATF) 
which inhibits AP-1 and downstream events including differentiation and 
proliferation (97). Thus, the PD-1 signaling pathway negatively influences T cell 
activation through diverse mechanisms that inhibit activation networks and 
upregulate transcription of inhibitory elements. Figure 1-4 depicts a schematic of 
PD-1 signaling inhibition. 
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Figure 1-4 – PD-1-mediated signaling inhibition. PD-1 Ligation recruits 
intracellular phosphatases and dampens TCR signaling by inhibiting PI3K activity 
which influences glucose metabolism and cell survival. Adapted from Keir et al. 
2008, Annual Review of Immunology. 
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PD-1 expression in disease 
The PD-1 pathway has been implicated as a factor exacerbating disease in 
several chronic infections including Helicobacter pylori, schistosomiasis, and 
leishmania (89, 98). Recent studies have shed more light on the manner in which 
PD-1 influences antigen-specific immune responses in chronic viral infections. 
Lymphocytic choriomeningitis virus (LCMV) infection in mice has been an 
important model system in the study of immune dysfunction in chronic infection 
for many years (99). The infection characteristics of two related LCMV strains are 
altered such that the Armstrong strain causes acute infection, which is rapidly 
cleared, and the clone 13 strain causes chronic infection that persists without 
clearance. As in other chronic infections with persistent antigen exposure, 
immune responses exhibit features consistent with immune exhaustion and 
dysfunction (76, 100). The availability of genetically similar viruses with distinct 
patterns of immunopathogenesis makes possible experiments comparing the 
same epitope-specific T cell responses in the context of acute or chronic 
infection…and so these experiments came to pass. 
 
Recently, a seminal study utilized the acute/chronic LCMV infection system to 
investigate the influence of PD-1 signaling in T cell dysfunction (78). Microarray 
analysis indicated dramatic upregulation of PD-1 in chronic LCMV infection. 
Subsequent analysis of ex vivo expression levels of PD-1 on the surface of T 
cells from acute and chronic infections confirmed that T cells in chronic infection 
expressed high levels which were sustained over time whereas PD-1 expression 
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on T cells in acute infection was downregulated within a few days after clearance 
of virus. Further experiments demonstrated that interruption of the PD-1 signaling 
pathway using antibodies to block PD-L1 was sufficient to induce modest 
reductions in viral load and restore some degree of T cell function in vitro, in vivo, 
and in the absence of CD4+ T cell help. A final interesting note from the study 
indicated that Pdcd1-/- mice could clear infection by the Armstrong strain with 
normal kinetics and immune responses but that Pdcd1-/- mice infected with the 
chronic clone 13 strain died of overwhelming immunopathology in less than 7 
days. Together, these results suggested for the first time that immunomodulation 
of the PD-1 pathway could lead to improved outcomes in chronic viral infection 
and that the inhibitory signals from the PD-1 pathway likely also play a role in 
limiting immunopathological damage from an overactive immune response in 
situations of persistent antigen exposure. 
 
Following initial characterizations in LCMV, several groups showed that PD-1 
expression was upregulated on T cells in various chronic viral infections in 
humans, including Hepatitis B (101)and C (102) (HBV and HCV), 
cytomegalovirus (CMV) (103), HIV (84-86), and simian immunodeficiency virus 
(SIV) infection (104). These groups noted that in ART-naïve individuals, PD-1 
expression correlates positively with viral load and negatively with CD4 counts, 
both of which are standards for measuring disease progression. Further 
experiments indicated positive correlations between PD-1 expression and 
apoptosis and inverse correlations between PD-1 expression and proliferation 
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potential. Importantly, and as shown previously in the mouse model, interrupting 
the PD-1 signaling pathway alleviated T cell dysfunction, reduced apoptosis, and 
increased proliferation and cytokine production in epitope-specific T cells from 
humans and non-human primates. 
 
Recent evidence implicates the exposure of epitope-specific T cells to their 
cognate antigen to increased PD-1 expression (105, 106) and suggests that the 
PD-1 signaling pathway may be an intrinsic and protective mechanism that works 
to reduce immunopathology in infections with ongoing immune activation and 
exposure. The expression patterns of PD-1 on clonotypes within epitope-specific 
responses were unknown and unexplored prior to this dissertation work. 
 
The immunomodulatory role of Interleukin-7 and its surface receptor  
Direct cell contact between receptor and ligand molecules on the surface of 
APCs and T cells is but one method of cell signaling which can influence T cell 
responses, development, and maintenance. Cytokines are immunomodulatory 
signaling proteins that play a central role in lymphocyte development, 
proliferation, survival, and function (107). These (mostly) unbound signaling 
molecules are produced and released by numerous cell types (many of them 
leukocytes), and they can have local paracrine or autocrine (108) effects as well 
as systemic pyrogenic effects (109). Mutations in cytokine genes or the genes for 
their receptors have wide-ranging deleterious effects on leukocyte and 
lymphocyte development and function. Many cytokines share common structural 
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motifs and thus receptor molecules for structurally related cytokines are similar in 
their own structures (110). The γc family cytokines derive their name from the 
fact that the cell surface receptors for each molecule share a common element in 
their γc receptor subunit. This family of cytokines includes interleukin-7 (IL-7), 
which is known to transmit essential and potent signals promoting naïve T cell 
development and effector T cell survival and development of memory (111).  
 
While evidence is clear that IL-7 signals influence immature lymphocyte 
development, we also know that IL-7 has an additional role in regulating T cell 
homeostasis in naïve and effector populations, even in the absence of antigen 
exposure (82, 110). Stromal and epithelial cells in the bone marrow and thymus 
and fibroblasts in the secondary lymphatics constitutively produce and secrete IL-
7. Investigations of IL-7 signaling and its influence on cell survival have been 
approached by assessing the distribution of the IL-7-specific receptor (CD127) on 
different cell populations (112). 
 
The IL-7 receptor is comprised of the common y-chain (CD132) and the IL-7 
receptor alpha subunit (CD127) (110). The shared y-chain receptor subunit 
invokes the recruitment of the Jak-Stat and PI3k pathways for cellular activation. 
The unique CD127 subunit, on the other hand, seems most responsible for the 
upregulation of anti-apoptosis molecules such as B cell lymphoma-2 (Bcl-2) and 
for the downregulation of pro-apoptotic factors like Bcl-2 associated X protein 
(BAX). Reduced cell surface expression of CD127 and susceptibility to apoptosis 
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has been noted in sub-populations of recently activated and short-lived effector T 
cells.  
 
Blattman et. al. studied epitope-specific responses in LCMV in the context of viral 
mutation, epitope escape, and subsequent reduction of exposure to cognate 
epitopes. They describe an inverse relationship between the expression of 
CD127 and PD-1 on epitope-specific T cells after the appearance of epitope 
escape variants and concurrent reduction in antigen exposure (106). My work 
demonstrates a similar pattern of CD127 and PD-1 expression on dominant and 
sub-dominant epitope-specific clonotypes in chronic HIV infection. 
 
Polyclonal epitope-specific T cell responses 
Clonal selection theory is a fundamental concept in immunobiology (113) and 
informs the existence of epitope-specific CTL populations that express 
genetically and structurally unique antigen receptors (T cell clonotypes) but which 
recognize the same pMHC molecule. T cells with broad reactivity for many 
peptide antigens are generated in the thymus, and it is thought that the human 
body has as many as a hundred or so T cells that recognize every peptide 
antigen potentially bound by that individual’s MHC molecules (1).  
 
Upon viral infection, circulating T cell clonotypes with a range of antigen affinities 
may each recognize, receive co-stimulation, and clonally expand in response to 
the same HIV peptide epitope (114). Concurrent expansion of these clonotypes 
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yields an eventual polyclonal population, which can be defined by its recognition 
of a single viral peptide epitope and comprises an epitope-specific population. 
Epitope-specific populations include at least one clonotype and often contain 
many clonotypes. Distinct T cell populations within epitope-specific responses 
can be identified by their usage of a finite number of TCRβ elements and 
corresponding genetic analysis of the TCRβ can establish clonality by confirming 
the expression of a unique CDR3 (115, 116). Statistical models can quantify the 
diversity of the epitope-specific TCR repertoire in terms of clonotype number and 
frequency (117) as well as in terms of the variety in amino acid sequences within 
TCRβ-CDR3 (118, 119). Research from different groups and studying different 
viral infections supports the notion that clonotypic and repertoire diversity plays a 
role in improved recognition of viral epitope variants (120, 121). 
 
T cell clonotypes – fundamental units of the T cell response 
Cytotoxic T lymphocytes are defined by their antigen receptors and their 
interaction with pMHC molecules. As such, T cell clonotypes form the 
fundamental units of T cell immunity (47). Daughter/sister cells within a 
clonotypic population have structurally identical T cell receptors. In this way, a 
polyclonal epitope-specific T cell response contains clonotypic populations that 
differ in their avidity for antigen and thus their capacity for functional responses 
and in their cell surface phenotypes. A significant body of literature describes 
HIV-epitope-specific T cell populations (84, 112, 122-126), and in this work, 
epitope-specific responses are often treated as homogenous populations of T 
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cells. However, a relatively small amount of research has been conducted to 
establish the important relationships between clonotypic recognition of epitope 
antigens, their function and phenotype, maintenance of the repertoire, or the 
manner in which individual clonotypic constituents might influence the epitope-
specific response (127-133). The data presented in this dissertation defines 
some of the relationships which mediate the phenotype and function of epitope-
specific clonotypes. 
 
Identifying epitope-specific T cell Clonotypes 
In the relatively recent past, multiple discoveries in monoclonal antibodies have 
been combined and applied using various technologies like flow cytometry to 
revolutionize the way immunobiology research is conducted (20, 134). 
Lymphocyte populations express patterns of surface proteins that are consistent 
and exclusive to different, distinct cell-type lineages these surface protein 
expression patterns define. The distribution of many of these populations is 
perturbed in HIV+ individuals compared to HIV- individuals (30, 135, 136). 
Monoclonal antibodies have been developed which bind specifically to various 
cell surface proteins. The conjugation of these monoclonal antibodies to 
fluorescent molecules allows immunologists to label cells with multiple ‘colors’ 
that can be used to define their lineage and cell surface phenotype. Multi-
parameter flow cytometry is used to analyze the presence or expression of many 
different fluorescent labels on single cells. In this way, peripheral blood cells from 
individuals can be labeled with a variety of fluorescently-tagged antibodies and 
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populations and sub-populations of their cells can be identified and compared to 
one another. 
 
Epitope-specific T cells in peripheral circulation can be positively identified 
through the use of MHC-I tetramer reagents (137). ‘Tetramers’ are comprised of 
4 MHC-I molecules, each of which have been loaded with a peptide and bound to 
one another and to a fluorescently-labeled molecule. By incubating T cells 
specific for the pMHC complex with cognate tetramers, epitope-specific cells can 
be fluorescently labeled and analyzed using flow cytometry. Epitope-specific 
populations can then be isolated using flow assisted cell sorting (FACS) or their 
sub-populations can be analyzed via multi-parameter flow cytometry (138). 
 
Individual T cell clonotypes within an epitope-specific response can be 
determined using several methods. Sorting epitope-specific populations and 
sequencing and analyzing the TCRβ chain CDR3 region is one method (127). A 
second method uses monoclonal antibodies to evaluate TRBV usage, but this 
cannot conclusively determine clonality within a TRBV population. Using flow 
cytometry and antibodies to identify TRBV usage as presented in the following 
research, clonotypes identified through genetic analyses can be confirmed and 
their surface phenotypes can be measured. 
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The ideal vaccine 
Successful vaccines stimulate acute immune responses that then contract into 
memory responses and subsequently protect the host from infection or 
pathogenesis. The discovery of adjuvants allowed enhancement of the immune 
response to many vaccine antigens and resulted in increased vaccine 
effectiveness (139). For many years, adjuvants have improved immune 
responses to vaccination with broad action and without a tremendous degree of 
specificity. Now, with a deeper understanding of the signaling networks which 
govern immune responses, the notion that vaccines and adjuvants could be 
designed to stimulate immune responses in a disease- or pathology-specific 
manner has finally come within reach.  
 
An optimal vaccine for HIV would generate an immune response that completely 
blocks infection by providing sterilizing cellular and humoral immunity. While 
these features might be ideal, vaccines that manage to provide sub-optimal 
responses and protection from pathology could also be beneficial in the absence 
of sterilizing immunity. Controlling infection by reducing symptoms to sub-clinical 
levels or decreasing viral replication and reducing subsequent transmission 
would both be favorable outcomes (140). Future vaccines may incorporate 
features to inhibit the PD-1 signaling network on epitope-specific T cells or 
enhance memory development or homeostatic proliferation stimulating the IL-7 
receptor molecule in order to directly influence specific cell types.  
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Thus far, HIV vaccines in humans have not elicited strong, durable immune 
responses that provide lasing immunity (7, 8, 18, 19). With few exceptions, 
experimental vaccines have also not shown efficacy in reducing viral loads to a 
great enough extent to influence disease outcomes. Research in SIV vaccination 
systems shows promise for approaches using electroporation of plasmid DNA 
encoding viral proteins (141). Recent investigations using T cell stimulatory 
cytokines to alleviate immune inhibition in concert with DNA or protein 
vaccination also provide encouraging results (142).  
 
Experimental evidence in mouse model systems of chronic LCMV infection 
suggest that interruption of the PD-1 signaling pathway can alleviate immune 
impairment and improve epitope-specific proliferation and cytokine production 
(143, 144). Subsequent vaccination protocols using PD-1 in the SIV infection 
macaque model provide similar results more relevant to HIV infection in humans 
(145). Strategies that incorporate PD-1 blockade into human papilloma virus 
(HPV) vaccination also show promise for enhancing T cell responses against 
HPV-mediated tumor cells (146). These successful experimental vaccination 
protocols, including concurrent stimulation of immune responses alongside 
interruption of immune inhibitory signaling, demonstrate that immune responses 
can be tuned to be more specific, robust, and durable than with stimulatory 
vaccination alone. My research will help inform the immunological effects these 
strategies may impart on the epitope-specific TCR repertoire. 
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Research Objectives 
My research defines the relationships between clonotypic dominance in the 
epitope-specific TCR repertoire and surface and functional phenotypes on 
epitope-specific clonotypes. These data provide insight into the immunological 
consequences of constant antigen exposure in chronic HIV infection and the 
influence of antiretroviral therapy and subsequent antigen reduction on clonotypic 
repertoire diversity and phenotype.  
 
In Chapter II, my work defines the relationship between high expression of the 
inhibitory marker PD-1 and low expression of the memory marker CD127 on 
dominant clonotypes within the epitope-specific TCR repertoire during chronic 
HIV infection. Furthermore, this work indicates that PD-1 expression on individual 
clonotypes may be influenced by avidity for cognate antigen, but that TCR avidity 
is not a singular mediator of clonotypic dominance within the epitope-specific 
TCR repertoire. Finally, this work shows that sub-dominant clonotypes retain 
higher levels of function compared to dominant clonotypes and suggests that 
they may play a role in the suppression of viral epitope variants. 
 
My work described in Chapter III represents data derived from longitudinal 
studies of TCR repertoire diversity and clonotypic phenotype within epitope-
specific T cell responses before and after the initiation of ART. These data clearly 
indicate that immune responses undergo several levels of remodeling after 
initiation of ART; the frequency of epitope-specific responses is reduced, memory 
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distribution is altered on T cell populations, and activation levels are reduced 
although the clonotypic hierarchy remains intact in most epitope-specific 
responses studied. Additional analysis of TCR repertoire diversity indicates a 
distinct pattern of TCR repertoire narrowing after initiation of ART. Despite 
unambiguous immunological changes after initiation of ART, pre-ART PD-1 
expression patterns on dominant and sub-dominant clonotypes remain durable 
even after the initiation of ART.  Taken together, these data suggest that overall 
maintenance of repertoire diversity may depend on high levels of generalized 
antigen exposure, but that epitope-specific T cells may still remain activated even 
during viral suppression as a result of low level antigen sensing. 
 
The prospect of enhancing the quantity and quality of immune responses to HIV 
through manipulation of immunomodulatory signaling pathways is a tantalizing 
goal. My findings better clarify the immunomodulatory networks which influence 
the generation, function, and survival of epitope-specific clonotypic T cells in 
chronic infection. As a result, this work provides insight into the potential effects 
of immunomodulatory therapies on the epitope-specific T cell receptor repertoire. 
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CHAPTER II 
 
DOMINANT CLONOTYPES WITHIN HIV-SPECIFIC T CELL RESPONSES ARE 
PD-1HI AND CD127LOW AND DISPLAY REDUCED VARIANT CROSS-
REACTIVITY 
 
Abstract 
 
HIV-epitope-specific T cell responses are often comprised of clonotypic 
expansions with distinct functional properties. In HIV+ individuals, we measured 
PD-1 and IL-7Rα expression, MHC-I tetramer binding, cytokine production, and 
proliferation profiles of dominant and sub-dominant T cell receptor clonotypes to 
evaluate the relationship between the composition of the HIV-specific T cell 
repertoire and clonotypic phenotype and function. Dominant clonotypes are 
characterized by higher PD-1 expression and lower C127 expression compared 
to sub-dominant clonotypes and TCR avidity positively correlates with PD-1 
expression. At low peptide concentrations, dominant clonotypes fail to survive in 
culture. In response to stimulation with peptides representing variant epitopes, 
sub-dominant clonotypes produce higher relative levels of cytokines and display 
greater capacity for cross-recognition compared to dominant clonotypes. These 
data indicate that dominant clonotypes within HIV-specific T cell responses 
display a phenotype consistent with ongoing exposure to cognate viral epitopes 
and suggest that cross-reactive, sub-dominant clonotypes may retain greater 
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capacity to suppress replication of viral variants as well as to survive in the 
absence of strong antigenic signaling. 
 
Introduction 
 
Evidence indicates that CD8+ T cell responses are a critical component of the 
natural immune responses to HIV (63, 64, 68). Epitope-specific CD8+ T cell 
responses appear to be impaired as a result of unique conditions present in HIV 
infection, namely constant antigen exposure (147) and overwhelming immune 
activation leading to exhaustion and eventual deletion of HIV-specific T cell 
responses (14). Our understanding of the mechanisms that underlie impaired T 
cell responses and their contributions to viral control remains incomplete. 
 
Reversible T cell exhaustion has been associated with the expression of high 
levels of Programmed Death-1 receptor (PD-1), especially on epitope-specific 
CD8+ T cells (78). PD-1 is a surface-expressed transmembrane signaling protein 
with extracellular homology to CD28 superfamily molecules and is upregulated 
on activated lymphocytes (89). The role of PD-1 in the development of functional 
T cell memory and resolution of acute infections is increasingly well defined using 
model systems such as lymphocytic choriomeningitis virus (LCMV) and in human 
infections such as human hepatitis B (78, 101). In the setting of chronic viral 
infection, however, the immunomodulatory role of PD-1 signaling becomes more 
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complex as the necessity to limit immunopathology can also dampen effective T 
cell responses that might contribute to viral clearance (31, 143). 
 
In HIV infection, PD-1 expression on T cell populations correlates positively with 
viral load (84) and likely contributes to increased sensitivity to apoptosis (85, 
148). PD-1 signaling blockade has been shown to restore some T cell function in 
LCMV infection as well as in vitro with T cells from HIV+ individuals (78, 86). A 
reduction in the expression of cytokine receptor molecules such as IL-7Rα 
(CD127) on epitope-specific T cells may also play an important role in the natural 
control of HIV (106, 149). Reduced T cell capacity to respond to homeostatic 
cytokines such as IL-7 represents a point of dysregulation in the maintenance of 
functional, long-lived antigen-specific memory (112, 150).  
 
Both quantitative and qualitative features of T cell responses are likely important 
for control of chronic viremia. The frequency of T cells that produce cytokine or 
proliferate in response to activation by cognate antigen is an important measure 
of the magnitude of the immune response (49, 122, 151), but qualitative aspects 
of CD8+ T cell responses such as the composition of the HIV-specific T cell 
receptor repertoire have been shown to be important in chronic viral infections 
such as hepatitis C virus infection (120) and HIV-1 infection (127). Activation or 
antigen exposure profiles of T cell subsets (80, 106), differentiation (67), or 
clonotypic antigen sensitivity (47) continue to provide important insight into 
potential mechanisms governing the generation and maintenance of optimal T 
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cell responses to chronic viral infections. Our previous work suggests that 
individual T cell clonotypes within HIV-epitope-specific responses are capable of 
responding independently to changes in viral load (127) and recognizing 
circulating viral variants (129).  
 
The relationship between the composition of the clonotypic T cell receptor 
repertoire and clonotypic phenotype or function has not been clearly defined in 
model systems or natural infections. We found that dominant clonotypes express 
relatively higher levels of PD-1 and relatively lower levels of CD127 in 
comparison to corresponding sub-dominant clonotypes. PD-1 expression 
correlated strongly with the ability of clonotypes to bind MHC-I tetramers, and 
while dominant and sub-dominant clonotypes were able to respond to stimulation 
with HIV peptide epitopes matching circulating sequence, sub-dominant 
clonotypes were more cross-reactive in response to common variant peptide 
epitopes. Additionally, dominant clonotypes displayed an impaired ability to 
survive in culture at low levels of antigen stimulation. These data provide insight 
into the relationships between the structural composition of HIV-specific CD8+ T 
cell responses, the relative antigen exposure of clonotypes within the epitope-
specific TCR repertoire, and the functional capacity of these clonotypes in 
ongoing HIV infection. 
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Materials and Methods 
 
Individual Cohort and HLA-typing. This cohort was organized within the 
Vanderbilt-Meharry CFAR and was comprised of anti-retroviral therapy naïve 
patients recruited through the Comprehensive Care Center (Nashville, TN). All 
individuals were typed for HLA Class I by DCI Tissue Typing Laboratory 
(Nashville, TN). This study was approved by the Institutional Review Board at 
Vanderbilt University, and all participating individuals provided written informed 
consent.  
Flow cytometric evaluation of lymphocyte surface molecules. Lymphocyte 
subsets were evaluated using fresh and cryopreserved peripheral blood 
mononuclear cells and a combination of monoclonal antibodies. CD3-AlexaFluor-
700 (BD), CD4-PE-Texas Red (Caltag), CD8-Pacific Orange (Caltag), CD14-
PerCP (BD), CD19-PerCP (BD), CD56-PE-Cy5 (BD), Viaprobe (BD), CD127-
biotin (eBioScience), Streptavidin-APC-Cy7 (BD), PD-1-pure (Mouse IgG1, clone 
EH12:2H7, BioLegend), goat-anti-mouse IgG-Pacific Blue (Molecular Probes), 
anti-TRBV-PE/FITC (Beckman-Coulter) and MHC-I tetramers-PE/APC. MHC-I 
tetramers: HLA-B*08-EI8 (EIYKRWII), HLA-B*08-FL8 (FLKEKGGL), HLA-B*15-
GY9 (GLNKIVRMY), HLA-B*15-TY11 (TQGYFPDWQNY), HLA-B*27-KK10 
(KRWIILGLNK) – synthesized by the NIH Tetramer Core Facility, Atlanta, GA. 
HLA-B*57-KF11 (KAFSPEVIPMF), HLA-B*57-IW9 (ISPRTLNAW), and HLA-
B*57-QW9 (QASQEVKNW) – synthesized by Beckman-Coulter.  
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Cells were labeled with MHC-I tetramers at 21ºC for 10 minutes. Anti-PD-1 
antibody was added to the suspension and incubated for a further 20 minutes. 
Cells were washed and labeled in separate steps with intervening washes with 
pacific blue conjugated goat anti-mouse antibody, normal goat Ig blocking 
antibody, anti-CD127-biotin, streptavidin APC-Cy7, and the remaining directly 
conjugated surface antibodies listed above. Gating strategy shown in Figure 2-1. 
Identification of dominant and sub-dominant clonotypes and TRBV 
populations. The phenotype of T cell clonotypes was determined by a 
combination of labeling with tetramer, anti-TRBV antibodies, and antibodies to 
cell surface markers. Single TCR clonotypes identified by sequencing, and which 
comprised more than 50% of the epitope-specific population were considered 
dominant. In TCR repertoires where no clonotype comprised more than 50% of 
the total, the largest population was considered dominant, and the remaining 
populations were considered sub-dominant. Monoclonal antibodies are not 
available to label TRBV7, so in the five cases where the dominant TRBV7 
clonotype was not directly labeled, TCR beta chain sequence data informed the 
identification of sub-dominant populations that were directly labeled. In these 
cases the unlabeled fraction of tetramer+ cells represented the dominant 
clonotypes. We determined TRBV repertoires for 11 epitopes in this study by 
using TRBV antibody panels (IOTest Beta Mark, TCR V-beta repertoire kit, 
Beckman Coulter). Dominant TRBV populations were definitively labeled within 
these responses, and sub-dominant populations were defined as 
tetramer+/TRBV-. 
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cDNA synthesis and TCR sequencing. Epitope-specific T cells were labeled 
with appropriate MHC-I tetramers and sorted by FACS to >95% purity on a 
FACSAria cell sorter (BD). RNA was extracted from sorted cells and anchored 
RT-PCR was performed with total RNA as previously described (128). PCR 
product was cloned into E.coli and sequenced on an ABI 3130xl automated 
sequencer (PE Applied Biosystems, Norwalk, CT). After editing and alignment 
using Sequencher (Gene Codes Corp., Ann Arbor, MI), TRBV/TRBJ usage was 
determined using the human TCR gene database (http://imgt.cines.fr/). T cell 
receptor variable region classification system of the ImMunoGeneTics database 
(IMGT) is used throughout this manuscript. 
Sequencing of autologous virus. Population viral sequence was obtained 
using viral RNA isolated from plasma (Qiagen) and reverse transcribed in one 
step (Qiagen) using HIV-Gag and HIV-Nef specific primers. DNA was amplified 
by PCR with the following primers: 5gag5–28 5’-GCG AGA GCG TCA GTA TTA 
AGC G-3’, 3gag1668–1693 5’-TCT GAG GGA AGC TAA AGG ATA CAG TT-3’, 
3gag1398-1420 5’-AAA ATT AGC CTG TCT CTC CCC AT-3’, 5nef1-19 5’-ATG 
GGT GGC AAG TGG TCA A-3’, 3nef691-708 5’-TGC TAG GCG GCT GTC AAA-
3’. Resulting PCR fragments were gel purified (Qiagen) and sequenced bi-
directionally on an ABI 3130xl automated sequencer using the same primers. 
Sequencher (Gene Codes) was used to edit and align sequences and 
identification was made using the Los Alamos HIV Sequence Database 
(http://www.hiv.lanl.gov/). 
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Intracellular Cytokine Staining. Intracellular cytokine staining assays were 
performed using 10ug/ml of indicated peptide, anti-CD28 and anti-CD49d MAbs 
(1 ug/mL each; BD) and GolgiPlug at 1ug/mL (BD). Cells were stimulated for 6 
hours and labeled with surface and intracellular antibodies. Surface staining 
panel: CD3 (AlexaFluor-700, BD), CD4 (PE-Texas Red, Caltag), CD8 (Pacific 
Blue, BD), CD14/CD19/CD56 (PerCP, BD), Fixable Live-Dead Aqua (Invitrogen). 
Intracellular cytokine production: IFN-γ (PE-Cy7, BD) and TNF-α (APC, BD). 
Positive (Staphylococcus enterotoxin B) and negative (unstimulated/media) 
controls were included for each individual. Reported cytokine production was 
subtracted from negative control values. Epitope variant panels: B*08-FL8 
[Consensus-FLKEKGGL, Variant 1-FLrEKGGL, Variant 2-FLKdKGGL], B*08-EI8 
[Consensus-EIYKRWII, Variant 1-dIYKRWII, Variant 2-EIYKRWIv], B*27-KK10 
[Consensus-KRWIILGLNK, Variant 1-KRWIImGLNK, Variant 2-KRWIvLGLNK], 
B*57-QW9 [Consensus-QASQEVKNW, Variant 1-QAtQdVKNW, Variant 2-
QAtQEVKNW] (peptide synthesis – Genemed, CA). 
Tetramer binding analysis. PBMC were washed in FACS buffer, resuspended, 
aliquoted, and labeled for 30 minutes at RT with tetramer (APC-conjugated) at 
the following dilutions from manufactured stock – 1:25, 1:50, 1:100, 1:200, 1:400 
final concentrations (~16uM to 4uM). With 5 minutes remaining for tetramer 
incubation, Live/Dead Fixable Aqua Dead Cell stain (Invitrogen) was added to 
each aliquot of PBMC. At 30 minutes, labeled cells were immediately washed 
with PBS and resuspended. Cells were fixed with 2% paraformaldehyde and 
washed in PBS. Fixed PBMC were first labeled with anti-TRBV-FITC conjugated 
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antibodies and subsequently with antibodies to surface markers CD3, CD4, CD8, 
and CD14/19/56 (fluorescent antibodies and manufacturers as detailed above) 
for 30 minutes at room temperature. Surface antibodies were fixed to cells a final 
time and analyzed immediately. 
In vitro culture and proliferation. PBMC were labeled with CFSE and cultured 
for 4 days in the presence or absence of peptide epitopes at the indicated 
concentrations. Cell culture media was supplemented with 1U/ml IL-2. Epitope-
specific and clonotypic proliferation was assessed by co-staining live cells with 
tetramer and anti-TRBV antibodies and measuring CFSE dilution. 
Statistical analysis. Comparisons between whole CD4+, CD8+, and epitope-
specific T cell populations were performed using Mann-Whitney tests. All paired 
comparisons were made using Wilcoxon matched pairs test. Fisher’s exact test 
for proportions was used to determine significance between PD-1 and CD127 
expression on dominant and sub-dominant populations. Spearman rank 
correlation was used to test for the relationship between PD-1 expression and 
avidity for tetramer. All statistics were calculated using GraphPad Prism, v5.01. 
Flow cytometry. All samples were sorted and data acquired on a FACSAria 
(BD) cell sorter. Data was analyzed using FACSDiva (BD) software. Plots shown 
using log10 fluorescence; histograms are log10 fluorescence vs. count. 
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Results 
 
Epitope-specific T cell populations express high levels of PD-1 
We evaluated the degree of PD-1 expression on total CD4+, CD8+, and HIV-
specific CD8+ T cell populations in 22 chronic HIV+ patients off anti-retroviral 
therapy (Figure 2-2). These individuals had varying levels of disease progression 
(Table 2-1, median VL=2474 copies/ml, range=<50-382,000; median CD4=688, 
range=132-1374). PD-1 expression (Mean fluorescence intensity, MFI) was 
measured on CD4+, CD8+, and 35 CD8+, HIV-epitope-specific T cell populations 
identified by MHC class I tetramers (Table 2-1, mean 1.6 epitopes/individual, 
range 1-5 epitopes/individual). As has been observed by other groups (84, 85), 
we found PD-1 expression to be higher on HIV-specific CD8+ T cell populations 
when compared to total CD4+ (p=0.007, mean 2.4 fold higher) and CD8+ 
(p=0.0003, mean 1.9 fold higher) T cell populations (Figure 2-2A and 2-2B).  
 
PD-1 expression on CD4+, CD8+, and HIV-specific CD8+ T cell populations was 
often bi-modal, and we were able to measure the percentage of PD-1high cells 
within a given T cell population. Tetramer+, HIV-specific populations have a 
larger fraction of PD-1high cells than CD4+ or parent CD8+ T cell populations 
(p=0.0001 and p<0.0001, Figure 2-2A and 2-2C). Despite overall high levels of 
PD-1 expression on epitope-specific T cells, we observed PD-1 expression as 
low as 40% on some epitope-specific populations, which may represent a subset 
of epitope-specific cells capable of greater function than PD-1high populations.  
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Figure 2-2 – PD-1 is highly expressed in a bi-modal pattern on epitope-
specific T cells in HIV+ individuals. Histograms showing PD-1 expression on T 
cell populations in a single individual, PD-1 MFI and percentage PD-1high values 
are provided in the corner of each histogram, CD8+ (top panel, purple), CD4+ 
(top panel, blue), and HIV-specific, tetramer+ (bottom panel, orange), A. PD-1 
MFI is higher on tetramer+ cells compared to CD4+ T cells (p=.007) and CD8+ T 
cells (p=.0003), B. Percentage of tetramer+ PD-1high cells is higher than the 
percentage CD4+ PD-1high T cells (p=.0001) and CD8+ PD-1high T cells (p<.0001), 
C. N=35 epitope-specific responses in 22 HIV+ individuals.
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Table 2-1 – PD-1 Study Cohort Demographic Data 
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10001** 2 378 1539 32030 M W 32 2 2, 2, 14, 15 
10002†** 3 664 1199 94 M W 43 21 3, 31, 27, 57 
10004†** 2 203 1091 50 M W 59 21 3, 30, 7, 57 
10015** 1 717 1462 98778 M W 42 3 1, 3, 8, 52 
10022†** 2 724 1254 292 M W 36 16 1, 31, 8, 27 
10027†** 5 775 1300 1893 M W 66 14 1, 2, 8, 57 
10035 1 429 663 2679 M AA 52 21 3, 33, 27, 44 
10038 1 510 646 1888 M W 48  9 2, 2, 27, 44 
10040 2 1161 972 50 F W 49 14 1, 31, 44, 57 
10060 1 688 1042 722 M AA 30 4 1, 33, 42, 57 
10069 1 1032 2005 2474 M AA 45 4 1, 30, 53, 57 
10070** 1 782 391 7115 F AA 28 10 23, 74, 57, 58 
10071† 2 743 414 50 F AA 45 14 1, 66, 8, 57 
10076 1 700 1500 21339 M AA 54 6 2, 30, 35, 57 
10086** 1 132 876 76427 M W 39 17 1, 29, 8, 44 
10094 1 546 928 14621 M W 44 8 1, 3, 7, 8 
10105†** 2 289 513 35050 F AA 54 4 1, 23, 8, 44 
10138** 2 231 NA 46800 M W 46 6 24, 29, 15, 44 
10141** 1 542 NA 382000 M W 46 6 1, 2, 15, 37 
20002 1 612 578 1556 M W 56 2 1, 2, 7, 27 
20004 1 720 1094 3714 M W 42 1 3, 32, 18, 27 
20018** 1 1374 1035 1886 M AA 24 2 2, 26, 40, 57 
# W - white, AA - African American      
† subjects followed longitudinally      
** subjects in CD127 sub-cohort      
NA - not available      
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Dominant TRBV populations within HIV-specific T cell responses are 
predominantly clonotypic and express higher levels of PD-1 and lower 
levels of CD127 compared to sub-dominant TRBV populations 
We next evaluated TRBV usage and clonotypic composition within HIV-specific 
PD-1high and PD1low populations. To identify T cell receptor usage within HIV-
specific CD8+ T cell populations, we sequenced FACS-isolated HIV-specific 
CD8+ T cell in combination with direct staining of PBMCs with HIV-epitope-
specific MHC-I tetramers and an anti-TRBV monoclonal antibody panel as 
previously described (67, 129). Twenty-one of 35 HIV-specific CD8+ T cell 
responses were sequenced to determine TRBV, CDR3, and corresponding TRBJ 
regions (Table 2-2) with subsequent repertoire confirmation using monoclonal 
anti-TRBV antibodies. Within each epitope-specific TCR repertoire, we identified 
a single, dominant CDR3 clonotype, although sometimes this dominant clonotype 
was found with other clonotypes within a single TRBV family (Table 2-2). For 
example, subject 10002 recognizes the HLA B*5701-restricted epitope IW9. 
Although we identified 8 clonotypes responding to this epitope, one TRBV27-
TRJ27 clonotype comprises 64% of the sequences. Two other clonotypes also 
use TRBV27, but combined, they only contribute to 6% of the total sequences. In 
this case, staining with anti-TRBV27 antibody was used to identify the dominant 
T cell clonotype for phenotypic analysis. We noted highly significant concordance 
between our two methods for repertoire determination (Figure 2-3A, r=0.86, 
p<0.0001). 
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Table 2-2 - TRBV CDR3 Sequences of Epitope-specific Populations 
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10001 TY11 TRBV10-3 CAISERAIRGTSGLTDTQYF TRBJ2-3 56 Vb12 64 50/67 
  TRBV10-3 CAISECAIRGTSGLTDTQYF TRBJ2-3 2   1/67 
  TRBV10-3 CAISERAIRGTSGLTDTQYL TRBJ2-3 2   1/67 
  TRBV4-2 CASSQAAGGRAFF TRBJ1-1 25 Vb7.1 36 11/67 
  TRBV4-2 CASSQAEGGQNHF TRBJ2-7 9   1/67 
  TRBV4-2 CASSLAPGGIAFF TRBJ1-1 5   3/67 
  TRBV4-2 CASSQAAGGRAIF TRBJ1-1 2   1/67 
10001 GY9 TRBV11-2 CASSLDSGFLEQYF TRBJ2-7 44 Vb21.3 44 18/36 
  TRBV10-3 CAISESGGRVDEQYF TRBJ2-7 36 Vb12 21 13/36 
  TRBV12-3 CASSPPSSYNEQFF TRBJ2-7 3 Vb8 11 1/36 
  TRBV4-3 CASSLQGAPEQFF TRBJ2-1 8 Vb7.2  3/36 
  TRBV11-3 CTSRLDPGFLEQYF TRBJ2-7 3 Vb21  1/36 
10002 KK10 TRBV7-2 CASSLYGEYEQYF TRBJ2-7 79 Ab unavailable 30/38 
  TRBV13 not identified by seq Vb23 4  
  TRBV6-6 CASSQGTTDTQYF TRBJ2-3 21   8/38 
10002 IW9 TRBV27 CASRPGQGGYEQY TRBJ2-7 64 Vb14 62 29/45 
  TRBV27 CASSSSTGQQPQH TRBJ1-5 4   2/45 
  TRBV27 CASRTQRWETQY TRBJ2-5 2   1/45 
  TRBV7-9 CASSLAQGWKTQY TRBJ2-5 20 Ab unavailable 9/45 
  TRBV7-9 CASSIQGLRATNEKLF TRBJ1-4 2   1/45 
  TRBV7-8 CASRSPLGYEQY TRBJ2-7 2   1/45 
  TRBV12-4 CASSSGTSGSAGYNEQF TRBJ2-1 2   1/45 
  TRBV5-1 CASSTNNEQF TRBJ2-1 2   1/45 
10002 QW9 TRBV27 CASRTQRWETQY TRBJ2-5 100 Vb14 93 13/13 
  TRBV4 not identified by seq Vb7.2 7  
10004 QW9 TRBV3-1 CASSQGPGERAGFNYEQY TRBJ2-7 56 Vb9 55 4/16 
  TRBV28 CASSLGYGYT TRBJ1-2 19 Vb3 29 3/16 
  TRBV27 CASSKGRYNEQF TRBJ2-1 25 Vb14 12 9/16 
10004 KF11 TRBV7-9 CASPHPDRPNYGYT TRBJ1-2 78 Ab unavailable 39/50 
  TRBV7-9 CASGGEFYGYT TRBJ1-2 16   8/50 
  TRBV19 CASSLTYGYT TRBJ1-2 2 Vb17 26 1/50 
  TRBV19 CASSSRTGGYGYT TRBJ1-2 2   1/50 
  TRBV24 CATSDRMDNEQF TRBJ2-1 2   1//50 
10022 KK10 TRBV12-4 CASSIAGGGEDTQY TRBJ2-3 31 Vb8 45 26/84 
  TRBV6-5 CASRKGQGDWEAF TRBJ1-1 5 Vb13.1 35 4/84 
  TRBV20-1 CSARGWVSNNQETQY TRBJ2-5 57 Vb2 20 48/84 
  TRBV20-1 CSARDPLPEASGGAGTDTQY TRBJ2-3 2 Vb2  1/84 
  TRBV19 CASTPPGF TRBJ1-2 1 Vb17  2/84 
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Table 2-2 (continued) - TRBV CDR3 Sequences of Epitope-specific Populations 
  TRBV27 CASSQWTGELF TRBJ2-2 4 Vb14  1/84 
10022 FL8 TRBV6-2 CASSFIPGQGTHYSNQPQH TRBJ1-5 78 Vb13.2 75 7/9 
  TRBV10-3 CAIRPFLGQDDNYGYT TRBJ1-2 11 Vb12 11 1/9 
  TRBV28 CASSLRGTGELF TRBJ2-2 11 Vb3 14 1/9 
10027 KF11 TRBV10-3 CAIGGHDYGYT TRBJ1-2 45 Vb12 54 40/88 
  TRBV6-5 CASSSLVNTGELF TRBJ2-2 23 Vb13.1 10 20/88 
  TRBV6-5 CALTGGDYGYT TRBJ1-2 7   6/88 
  TRBV20-1 CSARGWVSNNRETQY TRBJ2-5 14 Vb2 10 12/88 
  TRBV20-1 CAASTSAVLGKKGSQETQY TRBJ2-5 2   2/88 
  TRBV20-1 CSAREKGSQETQY TRBJ2-5 8   7/88 
  TRBV28-1 CASSGPGGEQY TRBJ2-7 1   1/88 
10027 FL8 TRBV2 CASSELGARVYEQYF TRBJ2-7 67 Vb22 70 37/42 
  TRBV10-1 CASSESSREVSYNSPLHF TRBJ1-6 6 Vb12 11 3/42 
  TRBV4-2 CASKEELSNTGELFF TRBJ2-2 23   1/42 
  TRBV29-1 CSVGDQGGSEQYF TRBJ2-7 4   1/42 
10027 EI8 TRBV13-6 CASTGGRGSPLHF TRBJ1-6 100 Vb13.1 95 45/45 
  TRBV9 Not identified by sequence Vb1 2  
  TRBV20 Not identified by sequence Vb2 1  
  TRBV28 Not identified by sequence Vb3 1  
10060 IW9 TRBV7-8 CASSQDRIHTEAF TRBJ1-1 94 Ab unavailable 52/54 
  TRBV13-2 CASSLGLDETQYF TRBJ2-5 6  5 2/54 
10070 KF11 TRBV7-9 CASSLGGGYT TRBJ1-2 50 Ab unavailable 22/44 
  TRBV7-8 CASEDFKNIQY TRBJ2-4 16   7/44 
  TRBV7-9 CASSPGQTNYGYT TRBJ1-2 14   6/44 
  TRBV7-9 CATPGEVLSPNYGYT TRBJ1-2 2   1/44 
  TRBV7-9 CASSLGGGQNGYT TRBJ1-2 2   1/44 
  TRBV7-6 CASSSMGGGTDTQY TRBJ2-2 2   1/44 
  TRBV7-9 CASSLAGGYT TRBJ2-2 2   1/44 
  TRBV11-2 CASSDGTGVGLGYT TRBJ1-2 5 Vb21.3 12 2/44 
  TRBV11-2 CASSDGQGRLGYT TRBJ1-2 2   1/44 
  TRBV14 CASSPRDSQETQY TRBJ2-5 2 Vb16 8 1/44 
10071 KF11 TRBV5-1 CASYNFGQYGYT TRBJ1-2 75 Vb5 67 20/25 
  TRBV7-6 CASSPMDLLDEQY TRBJ2-7 25 Ab unavailable 5/25 
10071 FL8 TRBV2 CASSELGATIYEQY TRBJ2-7 40 Vb22 46 8/20 
  TRBV4-1 CASSQEMNRVVGNEQF TRBJ2-1 25 Vb7.1 26 7/20 
  TRBV6-9 CASTRPGQGTYNEFQ TRBJ2-1 35 Ab unavailable 5/20 
10076 KF11 TRBV2 CASRGGSGELF TRBJ2-2 63 Vb22 87 34/54 
  TRBJ7-9 CASSGFRDRVNEQY TRBJ2-7 33 Ab unavailable 18/54 
10086 EI8 TRBV9 CASSVVGDSRETQYF TRBJ2-5 52 Vb1 80 24/46 
  TRBV9 CGSSVVGDSRETQYF TRBJ2-5 2   1/46 
  TRBV9 CASSTLRDSREKLFF TRBJ1-4 4   2/46 
  TRBV9 CASSTLGDSREKLFF TRBJ1-4 7   3/46 
  TRBV9 CASSADGSFYEQYF TRBJ2-7 2   1/46 
  TRBV27 CASSLVGQGARQPQHF TRBJ1-5 2 Vb14 9 1/46 
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Table 2-2 (continued) - TRBV CDR3 Sequences of Epitope-specific Populations 
  TRBV27 CASSLGSAKNIQYF TRBJ2-4 2   1/46 
  TRBV2 CASSEPPGVRGEAFF TRBJ1-1 9   4/46 
  TRBV4-1 CAGSQEFLNRRYF TRBJ2-5 7   3/46 
  TRBV5-1 CASSLSGSGWQETQYF TRBJ2-5 9   4/46 
  TRBV7-2 CASSLLPDPRSSGGYTF TRBJ1-2 2   1/46 
  TRBV7-8 CASSLLDGTRDQQYF TRBJ2-7 2   1/46 
10138 GY9 TRBV5-1 CASSEAGGTEAFF TRBJ1-1 46 Vb5.1 47 21/46 
  TRBV9 CASSVEGTILTDTQYF TRBJ2-3 13 Vb1 47 6/46 
  TRBV9 CASSVEGTIHTDTQYF TRBJ2-3 9   4/46 
  TRBV13 CASSLQQTLGAFF TRBJ1-1 9 Vb23.1 3 4/46 
  TRBV13 CASSPQQTLGAFF TRBJ1-1 9   4/46 
  TRBV20-1 CSALVEGDEQFF TRBJ2-1 4   2/46 
  TRBV20 CSAIVGSAYEQYF TRBJ2-7 2   1/46 
  TRBV29 CSVDGPTGGYTF TRBJ1-2 4   2/46 
  TRBV29 CASSQGLAGDEQYF TRBJ1-2 2   1/46 
  TRBV29 CSASLGGRISGANVLTF TRBJ1-2 2   1/46 
  TRBV14 CASSQDLRGARGYTF TRBJ1-2 2   1/46 
  TRBV14 CASSQGTGSTDTQYF TRBJ2-3 2   1/46 
  TRBV4-2 CASSQDSSGRVTGELFF TRBJ2-2 2   1/46 
10141 GY9 TRBV27 CASSDNGGDRSPGELFF TRBJ2-2 54 Vb14.1 67 21/39 
  TRBV27 CASSPSFPPDTQYF TRBJ2-3 10   4/39 
  TRBV27 CASSPGGGELFF TRBJ2-2 3   1/39 
  TRBV6-6 CASSSPGGVTEAFF TRBJ1-1 10 Vb13.6 10 4/39 
  TRBV6-6 CASSYSVVEAAAEAFF TRBJ1-1 2   1/39 
  TRBV20-1 CSARDRADRVLIPDTQYF TRBJ2-3 8 Vb2.1 6 3/39 
  TRBV20-1 CSASPVGGAYEQYF TRBJ2-7 5   2/39 
  TRBV6-5 CASRLGRLAYEQYF TRBJ2-7 3 1/39 
  TRBV6-5 CASSTLTGEDSGPQHF TRBJ1-5 3 
  
1/39 
  TRBV3-1 CASSQGLAGDEQFF TRBJ2-1 3   1/39 
20018 KF11 TRBV7-9 CASELSGNTIY TRBJ1-3 70 Ab unavailable 35/51 
  TRBV7-9 CASSYLNTIY TRBJ1-3 2   1/51 
  TRBV7-9 CASEGGNTIY TRBJ1-3 2   1/51 
  TRBV7-9 CATEASGNTIY TRBJ1-3 12   6/51 
  TRBV7-9 CASEITRDRRNTIY TRBJ1-3 2   1/51 
  TRBV7-6 CASSSWTGQDEQF TRBJ2-1 2   1/51 
  TRBV7-9 CASSGFTGFANEAF TRBJ2-6 2   1/51 
  TRBV28-1 CATSDLMDNEQF TRBJ2-1 4 Vb3 7 2/51 
  TRBV24-1 CATSDLMDNEQF TRBJ2-1 2   1/51 
  TRBV5-6 CASILTSGRNEQF TRBJ2-1 2 Vb5.2 3 1/51 
a Dark shading identifies dominant clonotype 
b Light shading identifies sub-dominant population(s) used for comparison (unshaded clonotypes were unlabeled) 
c TRBV populations directly labeled with antibodies are bordered 
d IMGT nomenclature for TRBV designation is used throughout the table and accompanying text 
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Figure 2-3 – Correlation between methods of repertoire determination. 
Epitope-specific TRBV repertoires were determined using two methodologies as 
described in Materials and Methods (sort/sequence and antibody labeling). 
Comparison of TRBV repertoire composition using these methodologies 
correlated strongly (r=0.86) and with high significance (p<0.0001, Spearman 
correlation), A.  
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We show representative plots of PD-1 expression on corresponding dominant 
and sub-dominant TRBV populations in a single HIV-epitope-specific T cell 
response (Figure 2-4A). Within HIV-epitope-specific responses, PD-1 expression 
is higher on dominant TRBV populations compared to sub-dominant TRBV 
populations when measured by MFI (p=0.001, Figure 2-4B) or frequency of PD-
1high cells (p=0.0001, Figure 2-4C). We evaluated multiple HIV-epitope-specific 
populations in 9 of 22 individuals studied (range 2-5 epitopes/individual, Table 2-
1 and Table 2-3). We did not find a correlation between the degree of dominance 
within the repertoire and the degree of PD-1 expression on dominant and sub-
dominant clonotypes within epitopes, suggesting that the magnitude of expansion 
within a parent population is not the sole determinant of PD-1 expression. 
 
If we limit our phenotypic analysis to those epitopes for which we have sequence 
confirmation that the dominant TRBV population is monoclonal, the relationships 
we highlight between clonotypic dominance and PD-1 and CD127 expression 
remain statistically significant (PD-1 MFI, p=0.0398; CD127 MFI, p=0.0342). 
Additionally, there are several ways to define clonotypic dominance within 
epitope-specific TCR repertoires in the absence of a single, highly dominant 
clonotype.  
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Figure 2-4 – PD-1 expression is higher on dominant TRBV compared to 
sub-dominant TRBV populations within epitope-specific responses. Dot plot 
and histogram showing PD-1 expression on dominant (blue) and sub-dominant 
(green) TRBV populations in a single epitope-specific response. PD-1 MFI and 
percentage PD-1high values are provided in the upper corner histogram for the 
dominant and sub-dominant TRBV populations, A. PD-1 expression is higher on 
dominant TRBV compared to subdominant TRBV as measured by MFI, B 
(p=0.001) and percentage PD-1high , C (p=0.0001). N= 35 epitope-specific 
populations in 22 HIV+ individuals. 
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Table 2-3 - TRBV Repertoire Data 
PID Epitope 
% of 
CD8 TRBV Repertoirea Methodb,c 
10001 TY11 2.2 10-3 (64%), 4-2 (36%) sort-sequence 
  GY9 1.5 11-2 (44%), 10-3 (21%), 12 (11%) sort-sequence 
10002 KK10 5.6 13-1 (4%), 7-2 (96%) sort-sequence 
 IW9 2.9 27 (62%), 7-9, 12-4, 5-1 (38%) sort-sequence 
 QW9 1.6 27 (92%), 4 (7%) sort-sequence 
10004 KF11 1.4 19 (26%), 7-9, 24 (74%) sort-sequence 
  QW9 1.1 3-1 (55%), 28 (29%), 27 (12%) sort-sequence 
10015 EI8 1.2 9 (71%), 2 (10%), 4 (5%) TRBV 
10022 KK10 19 12 (45%), 6-5 (40%), 2 (15%) sort-sequence 
  FL8 1.3 6-2 (75%), 10-3 (11%), 28 (14%) sort-sequence 
10027 KF11 0.5 10-3 (54%), 6-5 (10%, mult cdr3), 20-1 (10% multi cdr3) sort-sequence 
 FL8 0.8 22 (70%), 12 (11%) sort-sequence 
 EI8 0.4 6 (95%), 9 (2%) sort-sequence 
 QW9 0.8 28 (85%) TRBV 
 IW9 0.7 27 (86%), 4 (5% multi-Vb) TRBV 
10035 KK10 5.5 6 (62%), 19 (16%), 20 (15%), 12 (4%), 27 (3%) TRBV 
10038 KK10 1.3 6-2 (32%), 3 (24%), 4-2 (11%), 19 (20%) TRBV 
10040 QW9 2 6 (95%) TRBV 
  KF11 2 9 (94%) TRBV 
10060 IW9 1.5 13-1 (4%), 7-8 (96%) sort-sequence 
10069 QW9 2.6 6 (90%) TRBV 
10070 KF11 10 11-2 (12%), 27 (8%), 7 (80%) sort-sequence 
10071 KF11 1.8 5 (67%), 7 (33%) sort-sequence 
  FL8 3.7 2 (46%), 4-1 (26%) sort-sequence 
10076 KF11 7.4 2 (87%), 7 (13%) sort-sequence 
10086 EI8 1.8 9 (80%), 27 (9%) sort-sequence 
10094 FL8 3.7 27 (77%), 28 (7%) TRBV 
10105 FL8 1.8 6-2 (70%) sort-sequence 
  EI8 1.8 8-1 (45%) sort-sequence 
10138 GY9 2.1 5-1 (47%), 9 (47%), 13 (3%) sort-sequence 
 TY11 2.2 29 (52%), 9 (13%), 5-1 (12%), 13-2 (10%), 12 (8%) sort-sequence 
10141 GY9 0.8 27 (67%), 6-6 (10%), 20 (6%) sort-sequence 
20002 KK10 5.3 5-2 (45%) TRBV 
20004 KK10 2.4 27 (68%), 4-3 (12%) TRBV 
20018 KF11 11.2 28-1 (7%), 5-6 (3%), 7 (90%) sort-sequence 
a TRBV Repertoire - as determined by antibody labeling  
b sort-sequence - tetramer+, epitope-specific cells were sorted and subjected to TCR 
sequence analysis before co-staining with anti-TRBV antibodies  
c TRBV - tetramer+, epitope-specific cells were co-stained with anti-TRBV antibodies  
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However, even using a more stringent criterion that dominant clonotypes must 
comprise more than 70% of the TRBV repertoire (19 epitope-specific responses 
in 14 individuals fit this criteria), comparison between dominant and sub-
dominant clonotypes yields significant relationships for MFI and % PD-1high 
(p=0.03, MFI and p=0.001, % PD-1high, figure 2-5A and 2-5B). These data 
support our observations that dominant clonotypes express higher levels of PD-1 
despite relative differences in dominance within the clonotypic repertoire. 
 
We also evaluated CD127 expression on dominant and sub-dominant TRBV 
populations in a sub-cohort of 12 individuals, which included analysis of 19 
epitope-specific responses (noted in Table 2-1). In contrast to higher PD-1 
expression observed on dominant TRBV populations, CD127 expression was 
lower on dominant TRBV populations as measured by MFI (p=0.007, Figure 2-
6B) and frequency of CD127hi (p=0.05, Figure 2-6C) compared to corresponding 
sub-dominant TRBV populations. The PD-1 expression pattern described above 
on dominant and sub-dominant TRBV populations remains intact in this smaller 
cohort (p=0.006, PD-1 MFI). 
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Figure 2-5 – Alternative analysis of PD-1 expression on dominant 
clonotypes. PD-1 expression was measured by MFI (upper charts) and 
percentage PD-1high (lower charts) was compared between dominant and sub-
dominant TRBV populations when dominant populations comprised more than 
70%, B (n=19, p=0.03, p=0.001), or less than 70%, C (n=16, p=0.01 and p=0.03) 
of the overall epitope-specific repertoire (Wilcoxon matched pairs test was used 
for these comparisons). 
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Figure 2-6 – CD127 expression is lower on dominant TRBV compared to 
sub-dominant TRBV populations within epitope-specific responses. Dot plot 
and histogram showing CD127 expression on dominant (blue) and sub-dominant 
(green) TRBV populations for a single epitope-specific response. MFI and 
percentage CD127high values are provided in the corner of the histogram for the 
dominant and sub-dominant TRBV populations, A. CD127 expression is lower on 
dominant TRBV compared to sub-dominant TRBV as measured by MFI, B 
(p=0.007) and percentage CD127high, C (p=0.05). Measurements from 19 
epitope-specific populations in 12 HIV+ individuals. 
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Within this sub-cohort of epitopes labeled with PD-1 and CD127, 15 of 19 
dominant TRBV populations displayed a PD-1high phenotype and 15 of 19 
displayed a CD127low phenotype compared to their corresponding sub-dominant 
population.  
 
However, there was not complete concordance between these populations. The 
majority of dominant clonotypes (11 of 19) displayed the combination of higher 
PD-1 expression and lower CD127 expression. In contrast, there were no 
instances (0 of 19) in which the sub-dominant clonotype had both higher PD-1 
expression and lower CD127 expression (p<.0001). In summary, our data 
suggest that clonotypic dominance within the epitope-specific TCR repertoire is 
associated with a PD-1high/CD127low phenotype. 
 
PD-1high/CD127low phenotype on dominant clonotypes in HIV-specific 
responses is stable over time 
 
To characterize the stability of PD-1 and CD127 expression on dominant and 
subdominant TRBV population, we performed a longitudinal analysis of HIV-
specific responses from 3 individuals. Figure 2-7 details longitudinal viral load 
and CD4+ and CD8+ T cell number (Figure 2-7A), epitope-specific CD8+ T cell 
frequency and corresponding TRBV repertoire composition (Figure 2-7B), and 
PD-1 and CD127 expression (Figure 2-7C and 2-7D) on TRBV populations for 
the dominant clonotype within the HLA-B*08-FL8 response in 10022, the 
dominant TRBV population within the HLA-B*57-QW9 response in 10027 (this 
epitope-specific T cell population was not sequenced), and the dominant 
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clonotype within the HLA-B*57-KF11 response in 10071 for the most recent 6 
years of their infections (duration of infection 16, 16, and 15 years, respectively). 
10022 and 10071 are long-term controllers with stable viral loads and CD4+ T 
cell counts and 10027 is a chronically infected individual with progressive 
disease (increasing viral load and decreasing CD4+ T cell counts). 
 
Although expression levels of PD-1 and CD127 on the TRBV clonotypes within 
these HIV-specific responses are dynamic, the association of higher PD-1 
expression and lower CD127 expression with TRBV dominance remains 
consistent over the 6 years of our analysis. The B*08-FL8-specific TRBV 
repertoire in 10022 is relatively stable over time. The dominant TRBV2 
population in this individual maintains higher PD-1 expression over time whereas 
the sub-dominant TRBV populations have higher and increasing CD127 levels 
over the same period. The B*57-KF11-specific TRBV repertoire in 10071 is 
characterized by an increasingly dominant TRBV5 population and a 
corresponding increase in PD-1 expression compared to the subdominant 
TRBV7 population. 
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 In 10027, the B*57-QW9-specific TCR repertoire fluctuates early in our 
observations and as the TRBV28 population becomes dominant, its PD-1 
expression levels increase. Over this time period, 10027 experienced declining T 
cell counts and increasing viral load with an overall increase in PD-1 expression 
on CD8+ T cells. The dominant circulating viral sequence in 10022 and 10027 
was determined for the B*27-FL8 and B*57-QW9 epitopes at a midpoint in this 
analysis and corresponded to the peptide sequence within the tetramers in each 
case. 10071 maintained viral loads of <50 copies/ml during this study, and we 
were unable to generate viral sequences from this individual. 
 
We also evaluated mean PD-1 and CD127 expression levels at early and late 
timepoints on 10 additional epitope-specific responses and determined a similar 
and statistically significant expression pattern on dominant and sub-dominant 
TRBV populations (Figure 2-8). These longitudinal data suggest that dominance 
within the epitope-specific TRBV repertoire is associated with a more 
pronounced PD-1hi/CD127lo phenotype over time and may be related to the 
course of disease. 
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Figure 2-8 – PD-1high/CD127low phenotype on dominant TRBV populations is 
a stable relationship over time.  PD-1 and CD127 expression levels (MFI) were 
measured at multiple time points on dominant and sub-dominant TRBV 
populations and mean values were calculated for these populations over all time 
points.  Dominant populations had higher average expression of PD-1 MFI 
(p=.005), A, and lower average expression of CD127 MFI (p=0.003), B.  
Measurements from 13 (12 for the CD127 comparison) epitope-specific 
populations in 6 HIV+ individuals. 
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Tetramer binding characteristics of TRBV populations correlate with PD-1 
expression but are not directly related to dominance within the epitope-
specific TCR repertoire 
 
We next investigated whether differences in tetramer binding characteristics were 
related to dominance within the TRBV repertoire. Our group and others have 
previously described differential tetramer binding on epitope-specific T cell 
clonotypes (127, 133) and we observed a similar phenomenon in this study 
(Figure 2-9A). Several groups have previously used differential levels of tetramer 
binding to define T cell receptor avidity (133, 152), and so we measured tetramer 
binding (MFI) on TRBV populations over a 16-fold range of tetramer 
concentration and determined tetramer-binding curves for dominant and sub-
dominant clonotypes of 9 epitope-specific responses in 4 individuals (Figure 2-9B 
and Table 2-4). Non-linear regression analysis indicated that TRBV populations 
with lower half-maximal values have higher maximal binding values in 8 of the 9 
epitopes tested. Thus, we used tetramer MFI on labeled TRBV populations as a 
surrogate measure of TCR avidity for tetramer complexes. 
We compared tetramer binding levels on corresponding dominant and sub-
dominant TRBV populations. While there was a trend suggesting that dominant 
TRBV populations have higher avidity for tetramer than corresponding sub-
dominant populations, this pairing was not statistically significant (Figure 2-9C, 
p=.09). We found a positive and significant correlation between clonotypic avidity 
for tetramer and clonotypic PD-1 expression (Figure 2-9D, r=0.34, p=0.004). 
These data indicate that while clonotypic avidity for tetramer does not strictly 
67 
govern dominance within the repertoire, it may influence the degree of PD-1 
expression. 
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Table 2-4 - Tetramer Binding Characteristics 
  TRBV 
  
Tetramer 
concentration at 
1/2 Bmax(uM) Bmax (MFI) 
PID Epitope Dom Sub-dom Dom Sub-dom 
10004 KF11 6.64 3.40 9899 6596 
 QW9 1.26 1.58 7985 6329 
10022 KK10 0.13 0.35 2370 930 
 FL8 0.36 0.23 3009 2340 
10027 FL8 5.30 11.00 6542 5116 
 QW9 0.12 0.36 3910 2760 
 KF11 3.28 3.34 7811 3701 
10071 FL8 0.62 2.38 915 2323 
 KF11 0.12 0.28 4107 2678 
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Sub-dominant TRBV populations display greater cytokine production 
capacity and cross-recognition in responses to epitope variant peptides 
 
We assessed the capacity of dominant and sub-dominant TRBV populations to 
produce cytokines after stimulation with consensus and variant peptides. Two 
common viral sequence variants for each of 4 HIV-epitopes were tested in 7 
individuals. We performed viral sequencing in these individuals and found that 
circulating viral sequence matched the consensus epitopes used in the tetramer 
reagents in each individual except for 10094, who harbored a circulating 
sequence variant at the FL8 epitope which matched the FLKdKGGL variant we 
used in our functional assay (Table 2-5). 
 
Taking our analysis of the B*27-KK10 response in 10022 as an example, the 
dominant TRBV12 clonotype comprises 45% of the B*27-KK10 response which 
is 19% of total CD8+ T cells. The maximal possible cytokine production by the 
TRBV12 clonotype is therefore 8.6% of total CD8+ T cells. Likewise, maximal 
cytokine production for the sub-dominant clonotypes (TRBV6-5 and TRBV20-1, 
together 55% of the KK10-tetramer+ population) is 10.4% of total CD8+ T cells. 
We determined the relative cytokine capacity (RCC) of dominant and sub-
dominant TRBV populations by dividing cytokine production of the TRBV 
population by the frequency of that TRBV population within the tetramer 
population. By virtue of being a ratio, the RCC value for each TRBV population 
illustrates the extent to which it reaches its own maximal cytokine production 
potential without regard to its absolute percentage within the TCR repertoire. 
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Table 2-5 – Circulating Viral Sequence 
  Subject ID Epitope  
epitope 
sequence 
WT epitope  10022 B*27-KK10 KRWIILGLNK 
circulating 
epitope    ---------- 
  B*08-FL8  FLKEKGGL 
   -------- 
 10027 B*57-KF11  KAFSPEVIPMF 
   ----------- 
  B*57-QW9  QASQEVKNW 
   --------- 
 10071 B*57-KF11  KAFSPEVIPMF 
   
not 
determined 
 10086 B*08-EI8  EIYKRWII 
   -------- 
 10094 B*08-FL8  FLKEKGGL 
   ---D---- 
 20002 B*27-KK10 KRWIILGLNK 
   ---------- 
 20004 B*27-KK10 KRWIILGLNK 
   ---------- 
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Representative plots are shown in Figure 2-10A detailing cytokine production 
(IFN-γ – upper plots; TNF-α – lower plots) by the dominant TRBV12 clonotype 
and the sub-dominant clonotypes in response to stimulation with consensus and 
variant peptides for the HLA-B*27-KK10 epitope. In response to stimulation with 
consensus peptide, the TRBV12 clonotype reached absolute cytokine production 
levels of 8.1% (IFN-γ) and 3.4% (TNF-α) of total CD8+ T cells and the sub-
dominant clonotypes reached cytokine production levels of 8.1% (IFN-γ) and 
3.3% (TNF-α) of total CD8+ T cells. TRBV12 RCC values are 95% (IFN-γ) and 
40% (TNF-α). The sub-dominant clonotypes together comprise a larger part of 
the TCR repertoire than the dominant TRBV12 clonotype, and so despite similar 
levels of absolute cytokine production, their corresponding RCC values are lower 
at 78% (IFN-γ) and 31% (TNF-α). The strong cytokine response and high RCC 
values for the dominant TRBV12 clonotype suggest that these cells recognize 
consensus peptide more effectively than the sub-dominant clonotypes. 
Stimulation with the KRWIImGLNK variant peptide yielded similar results to those 
from consensus stimulation. In response to stimulation with the KRWIvLGLNK 
peptide, the dominant TRBV12 clonotype reached lower levels of absolute 
cytokine production and had lower RCC ratios for both IFN-γ and TNF-α 
compared to the sub-dominant clonotypes. The sub-dominant clonotypes 
preferentially recognized the KRWIvLGLNK peptide, produced their highest 
levels of absolute cytokine at 8.6% (IFN-γ) and 3.6% (TNF-α) of total CD8+ T 
cells, and reached their highest RCC ratios of 82% (IFN-γ) and 35% (TNF-α). 
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The B*08-FL8 response in this individual is represented in similar fashion in 
Figure 2-6B and yields similar results. 
 
Comparison of RCC values for the clonotypic cytokine responses in a further 8 
epitopes from 6 additional individuals (total, 10 epitopes in 7 individuals; Figure 
2-6C-D) reveals that both dominant and sub-dominant TRBV populations are 
capable of cytokine production to consensus peptides (Figure 2-6C, p>0.05 for 
IFN-γ and TNF-α production). In response to stimulation with common variant 
peptides, sub-dominant TRBV populations have higher RCC ratios for IFN-γ 
production (Figure 2-6D, p=0.04) with a trend toward higher sub-dominant RCC 
ratios for TNF-α production as well (Figure 2-6D, p=0.08). These results indicate 
that while dominant and sub-dominant clonotypes are capable of producing 
cytokines in response to stimulation with consensus and variant peptide 
epitopes, sub-dominant clonotypes seem to retain greater capacity for cross-
recognition and secretion of multiple cytokines in response to the common viral 
epitope variants we tested. 
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Figure 2-10 – Sub-dominant TRBV populations have high cytokine 
production potential in response to stimulation with variant peptides. 
IFN-γ and TNF-α production was assessed by ICS on dominant and sub-
dominant TRBV populations. Dot plots showing dominant (solid box) and sub-
dominant (dashed box) clonotypic cytokine production (IFN-γ, upper plots and 
TNF-α, lower plots) in response to stimulation with consensus and variant 
peptides for the B*27-KK10, A, and B*08-FL8, B, responses in 10022. Within 
each plot, absolute cytokine production for clonotypic populations as a 
percentage of total CD8+ T cells is shown to the right of each indicated 
population as well as relative cytokine capacity (RCC, in parentheses). Graphs 
representing cytokine production for each response are located below 
corresponding plots. Bars represent maximal cytokine production for dominant 
(grey) and sub-dominant (unfilled) clonotypes, absolute cytokine production (% 
of total CD8+ T cells) is represented by the hatched area within each bar, and 
RCC for each clonotype and condition is noted to the right of each bar, A and 
B. 
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Figure 2-10 – Sub-dominant TRBV populations have high cytokine 
production potential in response to stimulation with variant peptides.
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Figure 2-11 – Sub-dominant TRBV populations have high cytokine 
production potential in response to stimulation with variant peptides. IFN-γ 
and TNF-α production was assessed by ICS on dominant and sub-dominant 
TRBV populations. Comparison of clonotypic RCC ratios for IFN-γ and TNF-α 
production in response to stimulations using peptide matching consensus, A 
(p=0.42 IFN-γ and p=0.38 TNF-α), and variant (p=0.04 IFN-γ and p=0.08 TNF-α), 
B. Measurements from 10 epitopes in 7 HIV+ individuals.
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Dominant TRBV populations display a survival defect in culture 
 
Proliferation upon antigen exposure is an important measure of T cell function 
and has been associated with improved control of viral replication (49). We 
labeled T cells with CFSE and cultured them with varying concentrations of 
peptide for 4 days to assess changes to the epitope-specific TRBV repertoire and 
capacity for proliferation of dominant and sub-dominant TRBV populations. The 
ex vivo epitope-specific response and its clonotypic repertoire is shown for the 
B*57-restricted-QW9 response in 10002 (Figure 2-12A). Representative plots are 
shown to illustrate epitope-specific populations (Figure 2-12B) and CFSE dilution 
(Figure 2-12C) for the dominant and sub-dominant clonotypes after 4 days of 
culture with low (0.2 ng/ml) and high (200 ng/ml) concentrations of optimal 
peptide antigen. At the 200 ng/ml peptide concentration, the dominant TRBV27 
clonotype made up 91% of the total repertoire at the end of the 4 day stimulation 
period, reflecting the ex-vivo repertoire. However, at the 200 pg/ml concentration, 
the TRBV27 clonotype comprised 58% of the repertoire. Therefore while both 
dominant and sub-dominant TRBV clonotypes proliferate well in response to 
stimulation with higher concentrations of consensus peptide, the dominant 
clonotype does not survive as well at lower peptide concentrations and therefore 
does not maintain the same degree of dominance in vitro. Moreover, as 
measured by the percentage of CFSElow cells, the dominant TRBV27 clonotype 
proliferates better than the sub-dominant clonotypes in response to stimulation 
with consensus peptides, reflecting in vitro what happens naturally in vivo. 
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Aggregate data from 15 epitopes in 7 subjects indicate that dominant TRBV 
populations fail to maintain their dominance at low concentrations of peptide 
(p=0.0026, Figure 2-12D). Conversely, dominant TRBV populations more 
effectively maintain their level of dominance at higher concentrations of peptide 
stimulation (p=0.2078, Figure 2-12D). In this series of experiments, the addition 
of antibody to block PD-1/PD-L1 interaction did not significantly alter the relative 
proliferative capacity of dominant and subdominant TRBV populations over the 
short duration of this assay (data not shown). These results suggest that while 
clonotypic constituents may not expand well at low concentrations of stimulation, 
sub-dominant clonotypic populations are better able to survive culture conditions 
with low levels of antigen. 
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Figure 2-12 – Dominant epitope-specific TRBV populations display a 
survival defect at low peptide concentrations which is alleviated by 
increasing antigen stimulation. PBMC were cultured in the presence of 
peptide antigen at the indicated concentrations and TRBV repertoire 
composition was assessed by flow cytometry on day 4. Relevant percentages 
of parent are shown to the right of each population. Representative contour 
plots showing ex vivo T cell populations: B*57-QW9+ T cells (upper plot) as a 
percentage of CD8+ T cells; B*57-QW9 epitope-specific population and its 
constituent dominant (blue) and sub-dominant (green) TRBV populations 
(lower plot) as a percentage of the epitope-specific population, A. MHC-I 
tetramer labeling after 4 day culture in the presence of different concentrations 
of peptide antigen, B. TRBV repertoire composition was determined by 
antibody labeling for the dominant TRBV as a part of the B*57-QW9+ 
population. Dominant (blue) and sub-dominant (green) TRBV populations are 
indicated on each plot and their percentage composition of the B*57-QW9 
response is shown at the right of each box. CFSElow percentages are shown 
for each population in the upper left corner of each box, C. Aggregate data 
was compiled, and statistical comparisons were made between epitope-
specific TRBV repertoire composition ex vivo and after 4 days of proliferation 
in culture. Dominant populations fail to maintain dominance at low peptide 
concentrations (p=0.0026), but repertoire composition is not significantly 
altered at higher concentrations (p=0.2078), D. Wilcoxon signed rank test. 
Measurements from 15 epitope-specific populations in 7 HIV+ subjects.
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Figure 2-12 – Dominant epitope-specific TRBV populations display a 
survival defect at low peptide concentrations which is alleviated by 
increasing antigen stimulation. 
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Discussion 
 
Several groups have observed enhanced global expression of PD-1 on T cells in 
HIV+ individuals, with the highest level of PD-1 expression on HIV epitope-
specific cells (84-86). A detailed analysis by Day et al. found that different 
epitope-specific responses, even within the same individual, had differing 
degrees of PD-1 expression (84). This has led to speculation that the degree of 
PD-1 expression could be linked to the efficacy of viral control for individual 
epitopes (84, 153).  
 
In this study, we evaluated constituent clonotypes within epitope-specific 
responses and determined that clonal dominance within epitope-specific 
responses is associated with a PD-1high/CD127low phenotype, that PD-1 
expression correlates with clonotypic TCR avidity for tetramer, and that dominant 
clonotypes display defects in their ability to respond to variant peptide epitopes 
and survive in the absence of strong antigen signals. We found that the most 
dominant clonotype within an epitope-specific response tended to have the 
highest level of PD-1 expression (p=0.001) and the lowest level of CD127 
expression (p=0.007). We did not see a relationship between the overall 
magnitude of a response (or the degree of clonotypic expansion within a 
response) and PD-1 expression, suggesting that PD-1 expression may not be 
directed related to the level of T cell expansion or exhaustion, but could mark T 
cells which have recently been exposed to their cognate antigen (154).  
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In LCMV infection downregulation of PD-1 and upregulation of CD127 occurs 
after viral epitope escape (106), suggesting that ongoing antigen exposure is a 
key factor in pushing T cells toward a PD-1high/CD127low phenotype. Lichterfeld et 
al described progressive reductions in CD127 expression on high avidity HIV-
epitope-specific clonotypes which were eventually deleted (155), and more 
recent work by Steeck et. al found PD-1 expression on HIV-1 epitope-specific T 
cells decreased after in-vivo selection for escape mutations (147). While this 
recent work highlights the relationship between, PD-1, and CD127 expression on 
epitope specific responses (106, 112), the data we present here is the first to our 
knowledge which describes differential expression of these markers on individual 
T cell clonotypes and links dominance to specific differences in clonotypic 
function.  
 
We have shown that epitope-specific T cell populations are often comprised of a 
single dominant and various sub-dominant clonotypic populations that can 
respond variably to changes in viremia (127) and that these clonotypes have 
differing abilities to recognize epitope variants (129). Our more recent work 
demonstrates a relationship between TCR use and memory phenotype (128). 
Thus, our new finding that dominant and sub-dominant T cell clonotypes have 
phenotypic and functional characteristics linked to antigen sensing is yet another 
indicator that the fine-specificity of individual T cell clones plays a role in the 
evolution of epitope-specific immune responses. 
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The majority of individuals we sequenced had dominant circulating sequences 
matching HIV Clade-B consensus, with the exception of 10094 (Table  and data 
not shown), and this subject still preferentially recognized the consensus peptide 
over the circulating variant. Despite their PD-1high/CD127low phenotype, we 
present evidence that dominant T cell clonotypes able to recognize circulating 
viral sequences have the capacity to produce multiple cytokines after stimulation 
with consensus and variant peptide epitopes and that subdominant clonotypes 
have increased ability to recognize common HIV-1 epitope variants. Improved 
recognition of viral variants by sub-dominant clonotypes might also be influenced 
by the diversity of TCR clonotypes within these sub-dominant populations. Each 
of the epitope-specific responses we assessed is comprised of a single dominant 
clonotype and at least one and in some cases more than one sub-dominant 
clonotypes. Effective recognition of variant epitopes may also be a reflection of 
increased diversity within sub-dominant TRBV populations. 
 
Immune selection pressure mediated by CD8+ T cells can lead to viral mutation 
and epitope escape from immune recognition (156-158), therefore the frequency 
of circulating epitope variants and the degree to which individual clonotypes are 
able to recognize these variants may also play a role in the development and 
maintenance of the epitope-specific TCR repertoire. A recent study from van 
Bockel et. al. offers insight into the relationship between clonal evolution within 
the TCR repertoire in HIV+ individuals and viral epitope variation (131). Their 
work highlights TCR repertoire remodeling within HLA-B*27-restricted responses 
85 
to a viral epitope known to consistently undergo immune-mediated mutational 
escape (67). The authors in this study found that in the presence of epitopes that 
varied from consensus, dominant T cell clonotypes were maintained over time 
and expressed higher levels of CD127 compared to subdominant clonotypes. In 
contrast to van Bockel et. al. we found dominant clonotypes to have lower levels 
of CD127 compared to subdominant clonotypes. Our study was different in that 
we evaluated 35 different epitope responses (representing 8 discrete HIV 
epitopes) in 22 individuals, and in the majority of cases the circulating viral 
sequence corresponded to the tetramer peptide sequence. These findings are 
broadly complementary to our own; both data sets indicate that dominant 
clonotypes are surprisingly persistent in vivo over time and support the notion 
that broad epitope-specific TCR repertoires may contain clonotypes capable of 
recognizing and suppressing viral sequence variants. 
 
While we cannot rule out the possibility that some HIV+ individuals in our cohort 
harbored viral variants not covered by the consensus or variant epitope 
sequences we selected, the recently reported associations between PD-1 
expression and epitope escape (106) highlight the importance of this line of 
inquiry for future longitudinal in vivo and in vitro studies. The relationship 
between epitope exposure, recognition, escape, and corresponding epitope-
specific T cell phenotype and functional capacity seems to be tightly related, 
although the effects of persistent exposure to antigen and viral escape on 
repertoire composition or clonotypic impairment have yet to be determined. In 
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this cross-sectional study, we were unable to assess whether higher avidity 
clones had been deleted earlier in infection or whether circulating virus had 
already escaped immune control for all the epitopes studied.  
Despite the higher expression of PD-1 on dominant clonotypes, and the relative 
failure of these dominant clonotypes to survive at low peptide concentrations in 
vitro, blockade of the PD-1 signaling pathway did not result in significant 
enhancement of clonotypic proliferation or survival. Studies evaluating the effect 
of PD-1 blockade on proliferative capacity have typically found modest increases 
in proliferation (78, 84, 86). The lack of enhanced proliferation we saw may be 
due to the short duration of our assays, and to the inclusion of relatively healthy 
subjects with low viral loads. Future studies with combinations of PD-1/PD-L 
blockade and cytokine combinations may help us determine to what extent 
dominant clonotypes can be “rescued” in vitro.  
 
Previous reports in mouse influenza models (159) and human EBV/CMV 
infection (133) indicate that T cell avidity for antigen is positively correlated with 
dominance in the epitope-specific TRBV repertoire. Our data support the notion 
that clonotypic TCR avidity is associated with higher expression of PD-1, but 
suggest that the association between overall TCR avidity and clonal dominance 
may be weaker in the setting of chronic HIV infection. Prior studies evaluated 
either acutely resolved or chronic viral infections with limited antigen variability 
and low levels of ongoing antigen exposure during chronic infection, and those 
conditions could account for the discrepancies between our study and this 
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previously published work. It remains to be determined if the associations 
between epitope-specific clonotypic dominance, phenotype, and function which 
we report in HIV infection also apply to other infections in humans and model 
systems. 
 
T cell phenotype and function is determined not only by the fundamental 
interaction between TCR:pMHC but represents a sum of inhibitory and 
stimulatory signals emanating from surface receptor molecules such as PD-1 and 
CD127. Recent work from Almeida et al. (47) suggests that a composite measure 
for T cell function such as ‘antigen sensitivity’ might encompass not only avidity 
for antigen but a wide range of influential factors such as antigen receptor 
density, coreceptor-mediated signals, as well as activation status and expression 
of inhibitory signaling molecules. We suggest that the composition, phenotype, 
and functional profile of the clonotypic repertoire may be necessarily dynamic in 
order to respond to a highly variable pathogen such as HIV. 
 
The following model accommodates our observations and experimental results: 
dominant clonotypes preferentially expand to circulating viral epitopes in vivo. 
Dominant clonotypes express a surface phenotype consistent with ongoing 
antigen exposure and activation. Continued exposure to cognate antigen may 
erode the capacity of dominant clonotypic responses as a result of accumulated 
PD-1 signal inhibition and a reduction in homeostatic turnover from reduced 
CD127 expression. Sub-dominant clonotypes expand sub-optimally to circulating 
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viral epitopes in vivo and express a phenotype consistent with reduced exposure 
to antigen. Sub-dominant populations may recognize non-circulating or low-level 
variants more effectively than dominant populations and are exposed to relatively 
lower levels of their preferred cognate antigen resulting in lower overall antigen 
exposure and concomitant activation. This sparing effect results in the 
maintenance of a population of cells better able to survive in the absence of 
strong antigenic signaling. These data also suggest that higher avidity clonotypes 
develop a relatively PD-1high phenotype compared to lower avidity clonotypes and 
is consistent with the observation that higher avidity responses are deleted early 
in infection (155). It remains to be determined whether TCR repertoire 
composition or clonotypic phenotype in HIV is significantly different in individuals 
with confirmed viral escape or in the absence of antigen, although data from 
LCMV infection and HIV infection suggests that this might be the case (106, 131, 
147). 
 
A diverse epitope-specific TCR repertoire comprised of clonotypes capable of 
recognizing and suppressing both circulating and variant epitopes would be a 
beneficial outcome from either prophylactic vaccine strategies or for strategies 
seeking to broaden existing immune responses in established HIV infections. 
Furthermore, manipulation of immunomodulatory surface proteins such as PD-1 
or CD127 as a part of vaccination protocols could influence qualitative and 
quantitative aspects of the epitope-specific immune response including antigen 
sensitivity or clonotypic repertoire (143). Effective immunological strategies to 
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control chronic infections like HIV may require not only the generation or 
stimulation of antigen-specific cells but also a coordinated manipulation of 
inhibitory pathways. 
90 
CHAPTER III 
 
ANTI-RETROVIRAL THERAPY REDUCES THE MAGNITUDE AND T CELL 
RECEPTOR REPERTOIRE DIVERSITY OF HIV-SPECIFIC T CELL 
RESPONSES WITHOUT CHANGING T CELL CLONOTYPE DOMINANCE OR 
PHENOTYPE 
 
Abstract 
 
After initiation of highly active anti-retroviral therapy (ART), HIV viral loads 
decrease as do the magnitudes of HIV-epitope-specific immune responses. In 
chronic HIV infection, the virus-specific T cell receptor repertoire allows the host 
to respond to viral epitope diversity; however, the effects of antigen reduction on 
the T cell receptor (TCR) repertoire of epitope-specific CD8+ T cell populations 
are not well established. We determined the TCR repertoires of 14 HIV-specific 
CD8+ T cell responses from 8 HIV+ individuals before and after initiation of ART. 
We used multiparameter flow cytometry to measure the distribution of memory T 
cell subsets, and the surface expression of PD-1, CD127, and CD38 on overall T 
cell populations and T cell clonotypes within epitope-specific responses from 
these individuals. Post-ART, we noted decreases in the frequencies of circulating 
epitope specific T-cells (p=0.02), decreases in the number of T-cell clonotypes 
found within epitope-specific T cell receptor repertoires (p=0.024), and an overall 
reduction in the amino acid diversity within these responses (p<0.0001). Despite 
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this narrowing of the T cell response to HIV, the overall hierarchy of dominant T 
cell receptor clonotypes remained stable compared to pre-ART. CD8+ T cells 
underwent redistributions in memory phenotypes and a reduction in CD38 and 
PD-1 expression post-ART. Despite extensive remodeling at a structural and 
phenotypic level, PD-1 was expressed at higher levels on dominant clonotypes 
within epitope-specific responses before and after initiation of ART. These data 
suggest that antigen burden drives TCR diversity, and that dominant clonotypes 
are sensitive to very low levels of antigen. 
 
Introduction 
 
Successful anti-retroviral therapy (ART) reduces viral loads and decreases the 
level of T cell activation but the effect of HIV antigen reduction on the TCR 
repertoire of epitope-specific T cell responses remains poorly defined (160). The 
level of generalized T cell activation as measured by expression of CD38 is a 
strong, independent predictor of disease progression (61, 161). More recent work 
has shown a positive correlation between increased expression of PD-1 on T 
cells and the level of viremia (85, 112). In addition to being an independent risk 
factor for disease progression in the absence of ART, sustained high levels of 
immune activation in the presence of ART are associated with poorer levels of 
CD4+ T cell recovery (162). Other phenotypic markers such as CD45R0, CCR7, 
CD27, and CD28 define T cell memory subsets, which are altered as a result of 
HIV infection (32, 124, 136). After the initiation of ART, the distribution of memory 
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T cell subsets improves, indicating broad remodeling of T cell populations with 
successful treatment and antigen reduction (163). Few studies have evaluated 
the effect of ART on HIV-specific T cell populations in detail and even these have 
not analyzed the epitope-specific TCR repertoire in detail (160, 164-166).  
 
Virus-specific CD8+ T cell responses are a critical component of the natural 
immune response to HIV (63-65). However, quantitative features of T cell 
responses such as the frequency or magnitude of HIV-specific T cell responses 
do not correlate well with control of viral replication or disease progression (122, 
123). On the other hand, qualitative features of T cell responses such as epitope-
specific proliferation (49) and breadth of T cell effector function have been shown 
to correlate well with control of viremia (125) and may represent important 
determinants of disease outcome. Indeed, qualitatively superior, polyfunctional 
HIV-specific T cells have been shown to emerge after suppression of viremia 
with ART (167); however, after initiation of ART, the magnitude of HIV-epitope-
specific immune responses also contract (168). Clonotypic and amino acid 
diversity within the epitope-specific TCR repertoire is a qualitative feature of T 
cell responses that may be associated with control of viremia (120, 121), but 
there is little data to inform our understanding of how the TCR repertoire may be 
affected by ART. 
 
We hypothesized that the structural composition and clonotypic phenotype of 
epitope-specific responses may also be altered in individuals undergoing ART. In 
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this study, we compared amino acid and clonotypic diversity within the HIV-
epitope-specific TCR repertoire before and after initiation of ART. Furthermore, 
we analyzed memory phenotypes and expression of CD38 and PD-1 on 
dominant and sub-dominant clonotypes from these epitope-specific responses. 
After initiation of ART, we noted changes in memory subset distributions, and 
decreased activation of CD4+ and CD8+ T cell populations. The magnitude of 
HIV epitope-specific T cell responses decreased after ART, and this was 
accompanied by a reduction in TCR repertoire diversity as measured by the 
number of discrete clonotypes found within epitope-specific responses, as well 
as by measurement of TRBV-CDR3 amino acid diversity. However, dominant T 
cell clonotypes typically remained dominant even post ART, and these T cell 
populations retained a PD-1high phenotype compared to sub-dominant 
clonotypes. These findings provide insights into the forces which likely drive the 
evolution of the TCR repertoire, namely, that high levels of persistent antigen 
exposure may drive TCR repertoire diversity, and that even in the setting of 
sustained reduction in circulating antigen, dominant T cell clonotypes maintain a 
phenotype consistent with exhaustion. 
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Materials and Methods 
 
Individual Cohort and HLA-typing. This cohort was organized within the 
Vanderbilt-Meharry CFAR and was comprised of patients recruited through the 
Comprehensive Care Center (Nashville, TN) who underwent initiation of ART 
during the course of follow up. All individuals were typed for HLA Class I by DCI 
Tissue Typing Laboratory (Nashville, TN). This study was approved by the 
Institutional Review Board at Vanderbilt University, and all participating 
individuals provided written informed consent.  
T-cell sorting and TCR sequencing. Epitope-specific T cells were labeled with 
appropriate MHC-I tetramers and sorted by FACS to >95% purity on a FACSAria 
cell sorter (BD). TCR Repertiore Sequencing was carried out as described (169). 
Briefly, total RNA was isolated from sorted class I tetramer-specific cells with 
RNA-STAT-60 (Teltest inc., TX, USA). Anchored RT-PCR was performed using a 
modified version of the SMART (switching mechanism at 5' end of RNA 
transcript) procedure (Clontech, Mountain View, CA) and a TCRB constant 
region 3' primer (5’-ATT CCT TTC TCT TGA CCA TG-3’). cDNA amplification 
was performed using the TCR constant region based primer (5’-TTC ACC CAC 
CAG CTC AGC TC-3’) and 10X Universal Primer A Mix (Clontech, Mountainview, 
CA) . PCR products of 600–700 base pairs were gel purified (Qiagen, Valencia, 
CA), ligated into the TOPO TA vector (Invitrogen, Carlsbad, CA), and used to 
transform chemically competent Top 10 E. coli cells (Invitrogen, Carlsbad, CA). 
Bacterial colonies were selected, and screened for the presence of insert using 
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PCR with M13 primers. Selected colonies were sequenced with the Taq 
DyeDeoxy Terminator cycle sequencing kit (Applied Biosystems, Foster City CA) 
and capillary electrophoresis on a PRISM automated sequencer (Applied 
Biosystems, Foster City CA). In frame TCR Sequences were edited and aligned 
using Sequencher (Gene Codes Corp., Ann Arbor, MI) and compared to the 
human TRBV genes database (http://imgt.cines.fr) (170). The TRBV 
classification system of the international ImMunoGeneTics database (171) is 
used unless noted. 
Measurement of T cell receptor diversity: The diversity of the TCR CDR3 
region was performed was determined using the Shannon entropy (H) (118, 172) 
calculation for protein sites as described previously (119) by the formula: H = −Σ 
pilog2 pi where pi is the fraction of residues at a site that is amino acid type i. For 
amino acids in the CDR3, H can range from 0 (site contains only one amino acid 
in all sequences) to 4.32 (all amino acids are represented equally at this site). 
Positions that contained >50% gaps were excluded from analysis. Statistical 
values are expressed as mean or median plus or minus SEM. The diversity of 
TCR clonotypes was calculated using the Simpson’s Diversity Index (173) using 
the formula Ds=1- Σ ni(ni-1)/N(N-1), where ni is the TCR clone size of the 
clonotype and N is the total number of TCR sequences sampled. Comparisons 
between groups were performed using Mann-Whitney test or two-tailed Student t 
test, depending on data normality. Correlations were calculated using Spearman 
Rank test. GraphPad Prism v5.03 software was used for statistical analysis.  
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Flow cytometric evaluation of lymphocyte surface molecules. Lymphocyte 
subsets were evaluated using with anti-CD3-AlexaFluor-700 (BD), CD4-PE-
Texas Red (Caltag), CD8-Pacific Orange (Caltag), CD14-PerCP (BD), CD19-
PerCP (BD), CD38-PE-Cy7 (E-biosciences), CD45RO-PE-TexasRed (E-
biosciences), CD56-PE-Cy5 (BD), CCR7-pure (Mouse IgG2, clone 150503, R&D 
Systems), Viaprobe (BD), anti-PD-1-pure (Mouse IgG1, clone EH12:2H7, 
BioLegend), goat-anti-mouse IgG-Pacific Blue (Molecular Probes), anti-TRBV-
PE/FITC (Beckman-Coulter). Epitope-specific T cell populations were stained 
with MHC-I tetramers HLA-B*08-EI8 (EIYKRWII), HLA-B*08-FL8 (FLKEKGGL), 
HLA-B*15-GY9 (GLNKIVRMY), and HLA-B*15-TY11 (TQGYFPDWQNY) (NIH 
Tetramer Core Facility, Atlanta, GA) and HLA-B*57-KF11 (KAFSPEVIPMF), 
HLA-B*57-IW9 (ISPRTLNAW), and HLA-B*57-QW9 (QASQEVKNW) (Beckman-
Coulter). 
 
Cells were labeled with MHC-I tetramers at 21ºC for 10 minutes. Anti-PD-1 or 
anti-CCR7 antibody was added to the suspension and incubated for a further 20 
minutes. Cells were washed and labeled with pacific blue-conjugated goat anti-
mouse antibody, washed and blocked with mouse normal IgG antibodies, and 
labeled with the remaining directly conjugated surface antibodies listed above. 
Cells were then washed a final time before acquisition on a BDFACSAria 
instrument. Data was analyzed using BDDiva software v6.1. 
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Results 
 
Epitope-specific immune responses contract after ART 
ART dramatically reduces viral loads in HIV+ individuals and many individuals 
experience increases in CD4 T cell count or reductions in the phenotypic 
activation status of T cells. We determined the composition of the epitope-
specific T cell receptor (TCR) clonotypic repertoire as well as clonotypic cell 
surface phenotype of 14 epitope-specific CD8+ T cell responses from 8 HIV+ 
individuals before and after the initiation of highly active anti-retroviral therapy 
(ART) (Table 3-1). Six of eight individuals had increases in CD4+ T cell counts, 
and the cohort had a mean reduction in viral load of 2.3 log (p=.01; paired T test). 
One of the two individuals who failed to reconstitute CD4+ T cells is 10004. This 
individual had abnormally low CD4 T cell counts from his inclusion in our cohort 
in 2003, and it is not surprising to note that the CD4 compartment is not fully 
reconstituted in this individual. The mean number of days before suppression of 
viremia to below 50 copies/ml was 170. All individuals were eventually 
suppressed to below 50 copies/ml, and 5 of 8 individuals were fully suppressed 
to undetectable levels at the time of repertoire and phenotypic analysis (Table 3-
1). 
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Using MHC-I tetramer reagents, we identified and tracked 14 distinct HIV-
epitope-specific CD8+ T cell populations before and after initiation of ART. 
Overall, epitope-specific T cell populations measured post-ART contracted as a 
percentage of the parent CD8+ T cell population compared to pre-ART 
measurements (73% median decrease, Figure 3-1A, p=0.02). However, this 
effect was not universal. For example, The B*57-KF11 response in 10004 
increased as a percentage of the parent CD8+ T cell population after initiation of 
ART, while the B*57-QW9 response in the same individual did not increase to a 
similar degree indicating that individual epitope-specific responses can respond 
independently to reductions in viral load. 
 
T cell clonal dominance is maintained after ART 
Epitope-specific TCR repertoires were determined by labeling epitope-specific 
populations with MHC-I tetramers, isolating these cells using FACS, and directly 
sequencing the T cell receptor-B variable region. Clonotypic dominance within 
the repertoire was determined by sequencing and confirmed by co-labeling 
tetramer+ populations with anti-TRBV antibodies. TCR repertoire data generated 
independently using these two methods corresponds well and with a high degree 
of significance (Figure 3-2, Pearson r=0.85, p<0.0001). 
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Figure 3-1 – Epitope-specific responses contract but clonotypic dominance 
remains intact.  Epitope-specific responses contract after initiation of ART 
(p=0.021, n=14),A.  Dominant clonotypes maintain relative dominance after 
initiation of ART (p=0.6947, n=12), B. Patient identifier, epitope-specific 
response, and dominant TRBV population are indicated in the figure legend. 
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Several clonotypes varied in their relative frequency within the epitope-specific 
repertoire after initiation of ART, but dominant clonotypes remained dominant 
after initiation of ART in the majority of cases. No statistically significant patterns 
emerged from our analysis of changes within the TCR repertoire after initiation of 
ART (Figure 3-1B). Dominant clonotypes in the 10001 B*15-TY11 and 20023-
B*15-GY9 responses contracted significantly after initiation of ART to the point 
that they made up only minor clonotypic populations in the TCR repertoire. No 
relationship was apparent between contractions in the TCR repertoire and 
corresponding phenotypic measures in our study. We next evaluated the TCR 
repertoire of these epitope-specific immune responses in more detail.  
 
The epitope-specific T cell receptor repertoire narrows after ART 
We were interested in determining the effect of ART on the clonotypic 
composition and structural diversity of the T cell receptor repertoire within 
epitope-specific responses. Diversity within the TCR repertoire can be measured 
using several methods. Shannon entropy (H) provides a useful metric to assess 
the degree of overall amino acid diversity within the TRBV-CDR3 (118, 119) 
(120, 129). Diversity analysis using Simpson’s diversity index can account for 
both abundance of a clonotype as well as its proportion within the repertoire 
(117). We used both methods to evaluate T cell repertoire diversity before and 
after ART.  
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We calculated entropy (H) values for each amino acid position within the TRBV-
CDR3 regions of 12 epitope-specific responses in 8 individuals before and after 
initiation of ART (Figure 3-2A). Taking individual amino acid positions in each of 
the epitope-specific populations into account, post-ART entropy was reduced 
compared to pre-ART (p<0.0001). The total number of clonotypes measured 
post-ART was reduced from a mean of 6.5 clonotypes/response to 3.9 
clonotypes/ response (Figure 3-3A, p=0.02). The mean entropy values for each 
CDR3 region (i.e. the average of the individual CDR3 amino acid entropy values) 
for epitope-specific populations post-ART decreased compared to pre-ART 
values (Figure 3-3B, p=0.0269). Additionally, by measuring the number of 
clonotypes and their relative abundance in the epitope-specific TCR repertoire, 
we also show that diversity is reduced after initiation of ART (Simpson’s diversity 
index, Figure 3-3C, p=0.025). It is important to note that despite the smaller 
magnitudes of epitope-specific responses after initiation of ART, there was no 
correlation between the number of cells sorted and the number of clonotypes 
determined (Spearman correlation, r=0.33, p=0.15). This is consistent with our 
prior data (129). Taken together, these data provide compelling evidence that the 
epitope-specific TCR repertoire narrows after initiation of ART in terms of overall 
amino acid diversity as well as in the number of clonotypes within each response. 
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Figure 3-3 – TCR repertoire diversity is reduced after initiation of HAART.  
Total number of clonotypes within epitope-specific decreased after initiation of 
HAART (p=0.0205, 12 epitopes), A. Mean entropy decreased in 10/12 evaluated 
responses, (p=0.0537, 11 epitopes), B.  Reductions in diversity by Simpson’s 
diversity index (p=0.0251), C. 
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T cell populations undergo memory redistribution and reductions in 
activation status after initiation of ART 
 
T cell phenotype is governed by environmental signals and is likely influenced by 
the level of antigen burden. Compared to uninfected controls, T cell populations 
in HIV infection are associated with skewed T cell memory differentiation (32) 
and increased expression levels of CD38 and PD-1 (174). We used expression 
of CD45RO and CCR7 to measure memory distribution on T cell populations 
before and after initiation of ART. Our longitudinal analysis shows that 
CCR7+/CD45RO- (Tnaive) and CCR7+/CD45RO+ (Tcm) populations are 
reconstituted after initiation of ART. Mean Tnaive populations increase by 2.5 fold 
and Tcm populations increase by 1.8 fold (Figure 3-4A, B; Tnaive, p=0.0078 and 
Tcm, p=0.0494). However, epitope-specific populations did not undergo significant 
changes in memory phenotype after initiation of ART.  
 
In a similar fashion, we compared post-ART expression of CD38 and PD-1 to 
pre-ART expression (Figure 3-5A). Our analysis determined a 3.1 fold reduction 
in CD38 mean fluorescence intensity (MFI) and a 2.2 fold reduction in PD-1 MFI 
on CD8+ T cell populations (Figure 3-5B, CD38, p=0.0547; PD-1, p=0.0078). We 
did not observe statistically significant changes in the expression of these 
markers on epitope-specific populations. Overall, these results suggest that 
parent T cell populations in individuals receiving ART undergo phenotypic 
changes in memory distribution and activation status but that these changes are 
not directly mirrored in epitope-specific populations. 
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Figure 3-4 – CD8+ T cell memory populations are reconstituted after 
initiation of ART. CD8+ and epitope-specific T cells were co-labeled with CCR7 
and CD45RO to determine memory distribution, A. CD8+ T cell Tnaive and Tcm 
populations increased after initiation of ART (Tnaive, p=0.0078 and Tcm, 
p=0.0494). 
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Figure 3-5 – CD8+ T cell activation is reduced after ART while epitope-
specific changes are variable. CD8+ and epitope-specific T cells were co-
labeled with CD38 and PD-1 at pre-ART and post-ART timepoints, A. CD38 and 
PD-1 expression on CD8+ T cells is reduced after initiation of ART (p=0.0078), B.
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PD-1 expression patterns remain stable after initiation of ART 
 
Expression of PD-1 is closely related to antigen exposure and T cell exhaustion 
in several infection systems (93, 175, 176), and we have previously shown that 
PD-1 is more highly expressed on dominant clonotypes within epitope-specific T 
cell populations (Conrad et. al. 2011). Having demonstrated clonotypic 
remodeling after initiation of ART, we were interested in determining whether 
initiation of ART would influence the relationship between clonotypic dominance 
and PD-1 expression. 
 
Epitope-specific T cell clonotypes were identified using tetramer reagents and 
anti-TRBV antibodies and PD-1 expression was determined by co-labeling these 
populations with anti-PD-1 antibodies (Figure 3-6A). As previously reported, we 
observed a distinct pattern of PD-1 expression on dominant and sub-dominant 
clonotypes within HIV-epitope-specific T cell populations whereby dominant 
clonotypes within epitope-specific populations expressed higher levels of PD-1 
than did corresponding sub-dominant clonotypes. This pattern of higher PD-1 
expression on dominant clonotypes remained statistically significant post-ART 
(Figure 3-6B). We noted no significant relationships between clonotype 
dominance and expression of CD38, CD127, or CD57 (data not shown). These 
results indicate that while overall immune activation may decrease on the parent 
CD8+T cell population after initiation of ART, the environmental signals which 
influence PD-1 expression on epitope-specific clonotypes remain intact. 
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Discussion 
 
Clonotypes within the epitope-specific T cell receptor repertoire recognize viral 
epitopes with an exquisite specificity (115), and antigen exposure almost 
certainly drives their phenotypic qualities (106) (Conrad, Ramalingam et al. 
2011). Our data here demonstrate that after initiation of ART, epitope-specific T 
cell responses contract but that clonotypic dominance within the TCR repertoire 
is most often maintained, that the TCR repertoire narrows by number of 
clonotypes and by amino acid diversity within the repertoire, and finally that 
despite the clear effects within the immune system, dominant clonotypes remain 
PD-1high compared to sub-dominant clonotypes. While other studies have noted 
phenotypic changes on T cell populations (61, 163) and contraction of epitope-
specific responses (164, 177), this is the first report to our knowledge which 
assess diversity with in the TCR repertoire and clonotypic phenotype before and 
after initiation of ART. 
 
Our studies here analyzed the epitope-specific TCR repertoire in 14 epitopes in 8 
HIV+ individuals before and after initiation of ART using a variety of 
methodologies. The first method involved simply counting the number of 
clonotypes identified by sequencing. Method two used Simpson’s diversity index 
(117) to assess the number of clonotypes in a response and, importantly, also 
accounts for the frequency of each clonotype as a part of the whole population. 
The third method used calculations to determine entropy (H) by assessing the 
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variability of amino acids substitutions within the TCRβ-CDR3 expressed in a 
given epitope-specific TCR repertoire. Each method indicated with statistical 
significance that the clonotypic TCR repertoire narrows after initiation of ART. 
 
We have previously shown that reduced diversity within the epitope-specific T 
cell receptor (TCR) clonotypic repertoire is associated with epitope escape in 
chronic HCV infection and data from SIV-infected macaques show a similar 
effect whereby narrow TCR repertoires drive immune escape Our group has 
shown the dynamic nature of the HIV epitope-specific T cell receptor repertoire 
over the course of chronic infection (127). Individual T cell clonotypes differ in 
their fine specificity for wild-type and variant viral epitopes (115), and this extends 
to populations of T cell clonotypes to recognize circulating in-vivo epitope 
variants (127, 129). We recently demonstrated that epitope specific clonotypes 
have a skewed maturation phenotype (128), and our most recent extension of 
this work shows that dominant clonotypes express a PD-1high/CD127low surface 
phenotype and recognize circulating viral variants, whereas sub-dominant 
clonotypes are better able to recognize and suppress epitope variants [Conrad et 
al, 2011]. Taken together with the data presented here, we suggest that 
individual T cell clonotypes may preferentially contribute to recognition of discrete 
virus populations, and that a diverse T cell receptor repertoire may provide more 
effective control of viral replication. 
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We noted that epitope-specific T cell populations decreased in relative frequency 
after suppression of viral replication under ART. Presumably, and as suggested 
previously (164, 177), this contraction is a result of reductions in antigen 
exposure and corresponding decreases in antigen-mediated T cell expansion. 
Within these lower frequency epitope-specific responses, however, dominance 
within the clonotypic hierarchy was largely maintained after ART suggesting that 
the features of the immune response which are responsible for maintaining the 
clonotypic hierarchy are independent of absolute antigen levels. Various lines of 
research support the theory that TCR avidity for antigen is the driving factor in 
establishing and maintaining dominance within the TCR repertoire (133, 159) 
although clonotypic dominance may also result in deletion from the 
repertoire(155).  
 
If avidity is a primary biophysical determinant of dominance within the repertoire, 
it would fit the criteria outlined above of acting as a relative factor independent of 
absolute or systemic levels of antigen. An alternative theory to explain the 
unperturbed maintenance of the clonotypic hierarchy might be that with the 
dramatic reduction in viral antigen exposure, epitope-specific clonotypes become 
ambivalent to change and are maintained in the status quo. If this were the case, 
we might expect to observe deletion of the more highly dysfunctional dominant 
clonotypes, and indeed, in two epitope-specific TCR repertoires, we do observe a 
dramatic shift in dominance where the frequency of the pre-ART dominant 
clonotype contracts to much lower levels post-ART and previously sub-dominant 
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clonotypes increase in frequency. If, in these cases, the dominant clonotype had 
been generated in response to a viral variant epitope which had not been fixed in 
the viral population and after suppression of viremia another epitope sequence 
became predominant, even at low levels, we might expect a distinct lonotype to 
establish dominance in the TCR repertoire. Future studies should be directed at 
evaluating epitope sequence variation in the context of ART-mediated viral 
suppression as well as a further characterization of the mechanisms which 
influence maintenance of epitope-specific clonotypic hierarchies in the absence 
of antigenic activation or stimulation. 
 
We assessed cell surface phenotype on various cell populations. Activation and 
memory profiles on CD8+ T cells clearly change after initiation of ART. CD38 and 
PD-1 expression are reduced on CD8+ T cells but no pattern of overall reduction 
was apparent on epitope-specific populations in our study. In line with other 
studies indicating activation levels are strong prognostic indicators of disease 
progress and viral load (61, 163), reductions in activation are a positive indicator 
of clinical improvement in these individuals. We noted consistent redistributions 
within CD8+ T memory subsets which indicated Tnaive and Tcm repopulations 
after initiation of ART. Again, these results are in line with previously reported 
data (136, 178) which indicate that ART initiates a rebound of immune responses 
which more closely resemble those found in uninfected individuals. The changes 
we note on CD8+ T cell population support our hypothesis that these individuals 
underwent significant immune remodeling after initiation of ART. 
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While the changes we observed in activation and memory phenotype on CD8+ T 
cells after initiation of ART have been reported previously in other cohorts, the 
measurement of phenotypic changes after initiation of ART on epitope-specific 
clonotypes has not been reported. Recent findings from our group established a 
relationship between dominance in the epitope-specific TCR repertoire and a PD-
1high/CD127low phenotype (Conrad, Ramalingam et al. 2011). By assessing 
epitope-specific clonotypic T cell populations before and after initiation of ART, 
we noted that dominant clonotypes had a PD-1high phenotype compared to sub-
dominant clonotypes which had been established during chronic infection and 
which endured after initiation of ART. We did not note statistically significant 
relationships between clonotypic dominance and expression of CD38, CD127, 
CD57 or memory distribution before or after initiation of ART. The absence of 
these relationships conforms to results from a previous study in chronic HIV 
infection in the absence of ART which also found no relationships between 
dominance and CD57 expression or memory distribution (128). 
 
Our findings in regard to the durable nature of the PD-1high phenotype on 
dominant clonotypes have implications in a few different scenarios. As mentioned 
above, if dominance is established as a result of TCR avidity and if PD-1 
expression is predicated on antigen sensing as has been suggested by other 
groups in both the LCMV and SIV models as well as in naturally controlled HIV 
infection (105, 106), then, as in the maintenance of the TCR repertoire hierarchy 
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mentioned above, we might expect PD-1 expression patterns to be maintained 
by relative antigen exposure rather than as a result of absolute levels of 
circulating antigen. Furthermore, considering our observations that PD-1 and 
CD38 expression patterns were not universally reduced on epitope-specific 
populations or on their clonotypic constituents, we hypothesize that these cells 
continue to receive some level of antigen stimulation even after the dramatic 
antigen reductions seen after initiation of ART. Indeed, the increased expression 
of PD-1 and CD38 we noted on a few epitope-specific populations may suggest 
that these responses actually saw relative increases in antigen exposure after 
initiation of ART. A more detailed dissection of the mechanisms at work at the 
epitope and clonotypic level is necessary to more fully understand how epitope-
specific responses evolve over time in the context of ART-mediated suppression 
of viremia. 
 
With their expression of identical TCR, HIV-epitope-specific clonotypes represent 
the fundamental unit of the T cell response to HIV. A more complete 
understanding of how epitope-specific clonotypes are maintained over time in the 
presence and absence of their cognate antigen is of great interest as we seek to 
elicit effective, durable T cell responses via vaccination. Overall, the results we 
report here indicate that despite the dramatic decreases in viral load, increases in 
CD4 count, and decreases in systemic activation, the mechanisms which govern 
clonotypic expansion and phenotype within epitope-specific T cell responses 
remain intact at some level. While TCR avidity may be a key component, it is 
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likely not a singular determinant of clonotypic repertoire diversity or phenotype. 
Moreover, the mechanisms at work in these responses and the manner in which 
they interact remains obscure, and a more complete understanding of their 
nature requires further investigation. 
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CHAPTER IV 
 
DISCUSSION AND FUTURE OBJECTIVES 
 
Clonotypes are the fundamental units of T cell immunity 
A fine line separates immune responses which recognize, suppress, and clear 
pathogens from immune responses which are either too weak or dysfunctional to 
clear pathogens or too strong and cause immunopathology. The host immune 
response must have the capacity to recognize pathogen-derived antigens with 
exquisite specificity and mount a defense just strong enough to clear infection 
without causing collateral damage. Numerous lines of empirically- and 
experimentally-derived knowledge from cellular and genetic studies inform us 
that T cell responses are critical components of the immune response to 
suppress viral replication and control HIV disease (30, 63, 64, 68-71, 179). 
Despite this knowledge, no clear correlates for immune protection have been 
defined in HIV infection (140, 180). Recent findings, including my own work on 
epitope-specific clonotypic dominance and surface phenotype, yield insight into 
the features which regulate immune responses and mediate dysfunction in 
natural immune responses to chronic viral infections (14, 30, 33, 128, 165).  
 
Much of the work from our research group is founded on the notion that 
clonotypic diversity within the epitope-specific TCR repertoire contributes to 
improved recognition of highly variable epitopes within pathogen infections, and 
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several lines of inquiry support this (1, 120, 121, 127, 129, 181). Despite an 
unambiguous understanding that epitope-specific responses are usually 
comprised of multiple independent clonotypes which recognize antigens to 
differing degrees and with different functional outcomes (115, 127-130, 133), a 
relatively meager effort has been directed toward defining the phenotypic and 
functional nature of clonotypes within epitope-specific responses. The clonotypes 
which constitute heterogeneous epitope-specific T cell populations are the 
fundamental units of a T cell response to antigen (47). As such, studies of 
epitope-specific clonotypes can provide insight into the mechanisms which allow 
for their recognition of antigen, drive their subsequent expansion, and mediate 
their capacity to produce effector functions and proliferate in response to 
activation.  
 
Clonotypic dominance and dysfunction 
In characterizing ex vivo epitope-specific TCR repertoires in chronically infected, 
ART-naïve individuals, my work defined a marked PD-1high/CD127low phenotype 
on dominant clonotypes within CD8+ HIV-epitope-specific T cell responses 
(Conrad et. al, 2011). Functional experiments indicated that dominant clonotypes 
are primed to respond to circulating viral epitopes, that they are likely impaired 
for in vitro survival in the absence of antigen signaling, and that sub-dominant 
clonotypes may preferentially recognize and suppress variant epitopes. These 
ideas are represented graphically in Figure 4-1. 
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Figure 4-1 – Maintenance of the clonotypic hierarchy. Dominance within the 
clonotypic repertoire is established in response to circulating viral epitopes 
(clonotype A1). Sub-dominant clonotypes respond sub-optimally to circulating 
sequence (clonotype A2) and cross-react with low-level viral variant epitopes 
(clonotypes A3B2 and A4B2). 
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Furthermore, my findings indicate that clonotypic PD-1 expression patterns in 
naturally-controlled, chronic HIV infection are durable in the face of immune 
recovery, TCR repertoire narrowing, and suppression of viral replication 
subsequent to the initiation of ART. These research findings illuminate a distinct 
phenotypic and functional heterogeneity which segregates to independent 
clonotypes within epitope-specific responses, and it suggests that sensing 
cognate antigen drives clonotypic phenotype and expansion within the repertoire 
to a large degree. 
 
My work established that dominance in the HIV-epitope-specific clonotypic 
hierarchy is associated with a PD-1high/CD127low surface phenotype, one 
consistent with T cell impairment and immune exhaustion (80). Expression of 
PD-1, a co-inhibitory surface receptor, on whole T cell populations in HIV+ 
individuals has been associated with increased viral loads and decreased CD4 T 
cell count (84, 86) and expression on epitope-specific T cell populations has 
been linked directly to T cell exhaustion and ongoing antigen exposure in chronic 
infections in mouse models (106) and natural human infections (147). Moreover, 
various studies of PD-1 expression determined that interruption of PD-1 signaling 
improved cytokine production and proliferation in epitope-specific T cell 
populations (78, 84, 86) and reduced sensitivity of PD-1high populations to 
apoptosis (85). Reduced expression of CD127, a component of the IL-7 receptor 
complex, has been implicated as a marker of impaired memory differentiation in 
HIV infection (112). 
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My studies involved HLA-B-restricted HIV-epitopes from chronically infected 
individuals for reasons primarily related to reagent and sample availability. HLA-
B-restricted HIV-epitopes are more commonly recognized and exert more 
selective pressure on viral replication (68), but a few HLA-A alleles restrict highly 
immunodominant HIV epitopes which are widely recognized in human 
populations (71). Additionally, limited viral sequence data was generated in order 
to confirm that circulating viral sequences matched the consensus sequences 
used experimentally in our tetramer reagents. Finally, selection of viral epitope 
variants in my studies was based on the most common epitope variants (Los 
Alamos HIV Database) rather than informed by deep sequencing of autologous 
viral sequence to identify circulating and low level variants.  
 
In order to extend my initial findings, future research directions must be oriented 
around the strengths and expertise of our research group in characterizing 
epitope-specific TCR repertoires which arise in response to viral infection. Two 
broad lines of inquiry will enable us to better define mechanisms that underlie 
recognition of viral epitopes, development and maintenance of the TCR 
repertoire over time, and suppression of viral replication: 1 – Comprehensive 
investigation of TCR repertoires specific for consensus and variant epitopes as 
well as for the corresponding in vivo viral epitope sequences in HIV+ individuals 
over time, preferably beginning at time points prior to establishment of viral set 
point and chronic infection; 2 – Parallel determination of surface phenotype, 
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functional capacity, and signaling properties of epitope-specific clonotypes. This 
future work will require the investigation of additional HLA-A-restricted epitopes 
from HIV and other common viral infections, a more comprehensive strategy for 
establishing the presence or absence of viral sequence variants in circulation 
within an individual, as well as subsequent experiments informed by autologous 
sequence using viral variants to assess clonotypic function and signaling 
characteristics. 
 
Viral epitopes and epitope-specific TCR repertoires in HIV+ individuals 
Our research group has at its disposal many of the key elements necessary to 
expand our understanding of TCR repertoire composition and maintenance in 
diverse, natural human viral infections namely a cohort of chronically infected 
HIV+ individuals, facilities to perform ex vivo sorting of live T cell populations, and 
expertise in culture of primary T cells. Several very accessible lines of inquiry are 
possible based on the recent availability of tetramer reagents which facilitate 
identification of clonotypes within HLA-A-restricted epitope-specific responses to 
HIV, CMV, and EBV.  
 
Epitope-specific responses to two other chronic viral infections, cytomegalovirus 
(CMV) and Epstein Barr virus (EBV), are commonly detectable at relatively high 
frequencies within individuals in our HIV+ cohort. Research from other groups 
suggests that clonotypic TCR hierarchies in epitope-specific responses to CMV 
and EBV are stable over time but vary in differentiation status (182) and that T 
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cell responses to these herpesviruses may have some degree of cross-reactivity 
(183). The evolutionary history of HIV infection in humans is significantly shorter 
than that of CMV or EBV (31, 184), and comparison of T cell responses specific 
for these viruses in the context of HIV co-infection may yield useful insight into 
the mechanisms which allow for effective suppression of EBV and CMV 
replication while replication of HIV remains partially or completely uncontrolled. 
While some data has been reported using epitope-specific responses to CMV 
and EBV as convenient internal controls for investigations of HIV-epitope-specific 
responses (84-86), little is known about the phenotypic or functional nature of 
constituent clonotypes and their response to changes in corresponding viral 
antigen exposure. Moreover, a better understanding of the T cell responses to 
these viral infections in the context of HIV-mediated immunosuppression may 
provide insight into the dynamics of T cell responses and herpesvirus reactivation 
in the related field of transplant immunology (185, 186). 
 
Research groups have studied the effects of epitope variation on T cell activation 
and function (187) and have studied the dynamics of epitope-specific repertoires 
upon epitope-specific escape in a limited manner (131), but little research has 
put all the pieces of this puzzle together in a comprehensive manner. 
Experiments which carefully measure the changing composition of epitope-
specific TCR repertoires as they react to a variable antigenic epitope should be 
undertaken. This will require the occurrence of a few relatively special events - 
namely epitope-specific responses and clonotypic repertoires amenable to 
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longitudinal interrogation and viral epitopes which mutate to escape recognition 
of the TCR (as opposed to mutations which abrogate binding to the HLA 
molecule). Fortunately, recent developments in massively parallel sequencing 
technology (188, 189) show some promise in the ability to determine detailed 
analyses of both TCR repertoires and viral quasispecies. If these technologies 
are able to be scaled down to the point where small populations of sorted T cells 
or viral sequences from individuals with low levels of viremia could be 
sequenced, they may become a necessary component of future studies. 
 
In natural HIV infection, epitope-specific T cells are likely exposed to and 
activated by their specific cognate antigens as well as by related, but non-
cognate viral variants or escape mutants. The complex interplay of constant 
exposure and activation of epitope-specific clonotypes by related, but distinct 
antigens has not been well treated in the literature, and this avenue of 
investigation should be pursued. Indeed, activation as measured by CD38 
expression on T cells is a strong, independent predictor of disease progression 
(61) and is thought to be one of the underlying causes of immunopathogenesis in 
HIV disease (56, 58). Understanding how epitope variation affects the activation 
status of epitope-specific T cell populations is necessary in the assessment of T 
cell responses in the context of ongoing viral replication and immune activation 
found in chronic HIV infection. 
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Within our current and growing cohort of HIV+ individuals, a natural initial 
extension of my work would be further characterization of the phenotype and 
function of clonotypic constituents within epitope-specific T cell responses to HIV, 
CMV, and EBV in the same HIV+ individuals. These studies should include 
longitudinal investigations of TCR repertoires directed against epitopes restricted 
by HLA-A and HLA-B alleles and should be done in coordination with careful viral 
sequencing to determine not only corresponding circulating epitope sequences 
but also low frequency viral epitope escape variants. Several groups have 
demonstrated that epitope escape can influence surface expression of PD-1 and 
CD127 (106, 147, 187), but none at the clonotypic level. Van Bockel et. al. have 
recently published investigations indicating that dominant clonotypes within a 
single HIV-epitope-specific response persist over time and cross-react with 
epitope variants suggesting that exposure to circulating and low level variants 
likely impacts the composition of the clonotypic repertoire (131), findings my work 
largely agrees with. This group used novel tetramer reagents constructed using a 
common epitope variant peptide. Their findings indicated significant overlap in 
the clonotypes found within TCR repertoires which recognize both consensus 
and variant epitopes. Future experiments should include the use of both 
consensus and variant tetramer reagents to determine TCR repertoires which 
correspond to consensus and autologous variant epitopes. I hypothesize that in 
vivo dominant epitope-specific clonotypes will be directed against the 
predominant circulating viral variant, perhaps a consensus epitope, and that 
clonotypes identified as sub-dominant with consensus tetramer may actually be 
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dominant clonotypes when assessed using tetramer constructed with low-level 
autologous variant epitopes. 
 
Clonotypic dominance in the TCR repertoire 
The mechanisms which govern clonotypic dominance within the TCR repertoire 
have been scrutinized by a number of different research groups, and TCR avidity 
for cognate antigen was defined as a prominent determinant in the selection of 
dominant clones within an epitope-specific response (133, 190-192). However, 
TCR avidity for antigen seems also to be a double edged sword.  For the 
individual, maintenance of high avidity clonotypes is associated with lower viral 
set points in chronic infection, but the high avidity clonotypes themselves are the 
ones more likely to be deleted from a given response (155). Studies preceding 
establishment of HIV viral set point or simply closer to acute infection may yield 
interesting insight into the clonotypic dynamics within epitope-specific responses 
as well as show a more significant relationship between dominance and avidity. 
 
Clonotypes in my studies were defined by expression of a unique TRB-CDR3 or 
distinct TRBV usage, and statistical analysis of clonotypic PD-1 and CD127 
expression patterns shows a relationship between surface phenotype and 
dominance within the TCR repertoire.  These results imply that antigen signaling 
through unique clonotypic TCR likely influences cell surface phenotype. There 
was no statistically significant relationship to indicate that TCR avidity drove 
clonotypic dominance in our cohort, although there was a modest trend in that 
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direction. There was, however, a positive correlation between TCR avidity and 
PD-1 expression on clonotypes regardless of hierarchical status in the repertoire 
indicating that stronger recognition of antigen may be a determinant of PD-1 
mediated dysfunction on clonotypes. A similar analysis of dominance and 
memory phenotypes showed no significant relationship (128). These findings 
may be reconciled by considering that our cross-sectional study used tetramers 
constructed only with consensus peptide epitopes and might have assessed 
epitope-specific TCR repertoires in individuals for which HIV had already 
undergone escape mutation. In ‘escaped’ epitopes, the in vivo TCR repertoire 
would be primarily directed against a circulating variant epitope rather than the 
consensus peptide epitope in the tetramer. Almeida et. al. described T cell 
antigen sensitivity as a primary determinant of T cell function and suppressive 
capacity (47). These investigations, which utilized unimpaired clonal T cell 
populations that recognized the same HLA-B*27-KK10 epitope but with different 
functional sensitivities, highlight the necessity to investigate T cell responses at 
their most fundamental level, that of the epitope-specific clonotype.  
 
Future efforts to define the relationship between clonotypic antigen sensing may 
include experiments to define the functional qualities (sensitivity, proliferative, 
and suppressive capacities) of sister clonotypes within the same epitope-specific 
response. In order to have enough cells for experimentation, it may even be 
necessary to sort these clonotypic populations and grow out clones as previously 
described (47, 115, 130). We have some expertise in labeling small epitope-
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specific clonotypes and isolating these cells using FACS. While this is not a trivial 
task, sorting clonotypes of a given epitope-specific population and culturing these 
cells to suppress viral replication is feasible and such experiments might even be 
enhanced with the addition of reagents to inhibit or activate cell surface receptors 
like PD-1 or CD127 and thereby alter clonotype function. It would be of great 
interest if the functions of epitope-specific clonotypes could be tuned using 
exogenous signals such as cytokines or inhibitory signal blockade and might lend 
support to the notion that the epitope-specific repertoire itself could be 
manipulated in the context of artificial antigen stimulation or vaccination. 
 
Relieving clonotypic dysfunction through signaling inhibition 
Beginning with initial descriptions of CTLA-4 as a negative co-stimulatory 
molecule (44-46), our understanding of co-stimulatory networks on lymphocytes 
has developed rapidly in recent years. Other co-stimulatory molecules such as 
PD-1, BTLA (B and T lymphocyte attenuator), and ICOS (inducible co-stimulator) 
have been described since that time (42, 48, 98) and act in concert to regulate T 
cell responses through unique and overlapping functions, especially in the 
context of continuous antigen exposure and cellular activation as seen in chronic 
HIV infection. Since the seminal reports of reversible PD-1 mediated T cell 
impairment in mouse and human infections (78, 84, 86, 193), several other 
groups have investigated myriad molecules and signaling interactions which 
regulate T cell responses (95, 97, 154, 194) in chronic HIV infection. 
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It is clear that in the context of chronic HIV infection, ongoing viral replication, 
antigen exposure, and persistent immune activation, natural immune 
mechanisms are rendered dysfunctional and inadequate to the task of 
suppressing viremia (14, 31). It seems that some large part of the immune 
dysfunction may be caused by inhibitory mechanisms such as PD-1 (154, 195) 
which likely evolved to reduce autoimmunity and control runaway cellular 
activation after acute infection (78, 93, 98). The tantalizing feature of this sort of 
immune dysfunction, however, is that signaling pathways originating from ligation 
of surface receptors may be interrupted outside the cell before they are received 
and thus the dysfunction might be alleviated. With a growing understanding of 
the intracellular events differentiating signaling pathways like CTLA-4 and PD-1 
(194) and downstream transcriptional events (97), it may be possible to inhibit 
the inhibitory pathways at an intracellular level. Signaling interventions show 
promise in mouse and non-human primate vaccination systems where immune 
stimulation by vaccination in concert with interruption of the inhibitory PD-1 
signaling pathway gives rise to strong cellular immune responses which show 
improved efficacy in controlling viral replication (144, 145). Our findings indicate 
that cell surface receptor phenotypes are related to dominance within the TCR 
repertoire and TCR avidity which suggests that vaccination protocols which 
include immunomodulation might influence the clonotypic composition of the 
repertoire. 
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In conclusion, my work demonstrates that clonotypic phenotype and function are 
closely associated to expansion within the TCR repertoire and antigen sensing. 
These novel findings can inform further, more detailed investigations of epitope-
specific responses in chronic controlled viruses as well as investigations to 
provide insight into the cellular mechanisms involved in maintaining epitope-
specific clonotypic repertoires to variable and static viral epitopes. Future studies 
will seek to better understand the development, maintenance, and functional 
capacity of the TCR repertoire in the face of chronic viral infection.  The 
immunopathogenesis of HIV poses difficult questions for the field, but as we gain 
insight into how immune responses develop and are maintained, answers reveal 
themselves. Ultimately, the insights we provide can inform our approaches for 
immunomodulatory therapies for HIV and other infections. 
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